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Abstract 
The failure of lung cancer treatments has been attributed partly to the development of 
drug resistance, however the underlying cellular and molecular mechanisms are poorly 
understood. It has been suggested that a very small group of specific cells within the 
heterogeneous tumors, cancer initiating stem cells (CSC), develop resistance to 
treatment, survive and later initiate the growth of new tumors. Due to their pivotal role in 
maintenance and relapse of tumors following the acquisition of drug resistance, we 
reasoned that novel drugs targeting cancer cells and CSC might provide the most 
effective treatments, if not a cure. To this end, we reported a polymeric nanofiber 
scaffold on which tumor cells develop into tumor organoids termed “tumoroids” that 
resemble in vivo tumors. Herein we report that lung cancer cells grown on the scaffold 
acquire CSC properties (aldehyde dehydrogenase (ALDH) activity, sphere formation, 
and tumor initiation). We have identified two key pathways that regulate this expansion 
namely Natriuretic Peptide Receptor A signaling (NPRA) and Wnt/β-catenin signaling. 
Screening of an NCI Diversity set identified a lead candidate drug targeting CSC, 
namely Actinomycin D (AD). AD is a well-studied anti-cancer drug, however it is known 
to have several drawbacks including high clinical toxicity and the development of 
resistance. In order to overcome these drawbacks, we tested AD treatment in 
combination with the angiotensin receptor antagonist, Telmisartan (TS) because it has 
been reported to reduce fibrosis in tumors allowing them to be more permeable to 
drugs. We have found that this novel combination treatment is effective in blocking CSC 
xiii 
 
enrichment in the polymeric nanofiber scaffold model. Furthermore, we demonstrate the 
effectiveness and synergistic action of the combination treatment in both an in vivo 
syngeneic mouse model and xenograft model revealing its ability to reduce tumor 
burden. We also provide evidence that β-catenin activation is at least partially 
responsible for the increase in CSC seen in scaffold culture and that the combination 
treatment reduces tumor burden in part by inhibiting Wnt/β-catenin pathway. This work 
establishes the utility of the scaffold-inspired tumoroids as a model system capable of 
enriching CSC in vitro or ex vivo for targeted drug screening and personalized medicine. 
It also identifies a promising novel treatment targeting CSC that, with further study, may 
be useful to improve therapeutic outcomes for lung cancer.
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Chapter 1 
Introduction 
 
1.1      Objective 
The objective of this dissertation is to characterize the expansion of lung cancer 
stem cells (CSCs) in a novel 3D cell culture environment and explore the molecular 
mechanisms by which 1) The 3D cell culture environment contributes to the expansion 
of CSCs and 2) A novel combination therapy is able to target and eradicate lung CSCs. 
 
1.2      Motivation 
The motivation for this work is to create an in vitro model to expand the rare CSC 
population in solid tumors, thus facilitating study of their properties and the screening of 
compounds for the ability to inhibit their growth. Using our model we have identified a 
combination therapy that is able to inhibit the growth of CSCs and reduce tumor burden. 
The work presented herein will describe how this treatment modulates the Wnt/β-
catenin signaling pathway in cancer cells to decrease their self-renewal and proliferation 
ability, ultimately resulting in cell death by apoptosis.  
 
1.3      Scope The scope of this project is to achieve a better understanding of the 
growth of CSCs in the tumor microenvironment and to identify therapeutic interventions 
to stop their growth through the use of a novel 3D in vitro model. These results will be 
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confirmed using in vivo models in order to validate the in vitro findings and confirm the 
utility of the novel model system. Lung cancer is currently the world’s deadliest cancer 
and new treatments are desperately needed to improve patient care. In the future, the 
findings presented herein may be further developed into such a treatment by revealing 
mechanisms to target and eradicate tumor initiating CSCs.     
 
1.4      Overview  
    Chapter 2 will introduce background information on CSCs describing their discovery, 
role in the tumor microenvironment, identifying biomarkers, models currently used to 
study them, and efforts to target CSCs in the clinic. Chapter 3 will describe in detail, all 
experimental designs and methods used. Chapter 4 will explain how a novel 3D cell 
culture environment was used to promote stem-ness in lung cancer cell lines in vitro. 
Chapter 5 will explain how this in vitro model can be used to study signaling pathways 
influencing the growth of CSCs, with a focus on the natriuretic peptide receptor A 
pathway. Chapter 6 will introduce a novel combination treatment and characterize its 
effects in the in vitro 3D CSC model as well as in vivo mouse models. Chapter 7 will 
describe the molecular mechanisms responsible for the treatment’s effects, focusing on 
the Wnt/β-catenin pathway. Finally, chapter 8 will summarize all results of this study and 
comment on its contributions to the field of CSC research and its implications for 
development of more effective cancer treatments. 
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CHAPTER 2 
 BACKGROUND 
 
2.1 Clinical Significance of Lung Cancer and Unmet Need for Treatment 
Lung cancer is currently the second most common type of cancer in men and women 
(following only prostate cancer in men and breast cancer in women) [1]. However, lung 
cancer is by far the deadliest type of cancer in both men and women causing over 
154,000 deaths in 2018 in the U.S. alone [2]. This represents approximately 25% of all 
cancer deaths. The five-year survival rate for patients with lung cancer is one of the 
lowest of any cancer at 18.6%,, while the overall five-year survival for cancer patients is 
66.9% [3]. Lung cancer is typically divided into two main morphological categories; 
small cell (SCLC) and non-small cell (NSCLC). Non-small cell is by far the most 
common type accounting for 80% - 85% of all lung cancer cases, therefore this project 
will focus on models of NSCLC with possible future application to SCLC and other 
cancer types.  NSCLC is further divided into three main sub-types, adenocarcinoma 
(currently 40% of cases), squamous cell carcinoma (30%), and large cell carcinoma 
(15%) with the remaining 15% made up of many rare sub-types[4]. While smoking is the 
largest risk factor for both small cell and non-small cell lung cancer, age should also be 
considered as the majority of diagnoses are made in patients over 65 and very rarely in 
patients younger than 45.   
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     Standard of care treatments for lung cancer vary depending on sub-type and stage 
at the time of diagnosis. There are many options available including surgery, radiation, 
chemotherapy, targeted therapies, immunotherapies, and combinations of the above. 
Despite this, over half of lung cancer patients die within one year of diagnosis. This high 
mortality rate is largely due to the development of drug and radio-resistance within 
tumors during treatment. For example, in recent years many drugs targeting common 
driver mutations in lung cancer such as those in the epidermal growth factor receptor 
(EGFR), anaplastic lymphoma kinase (ALK), MET proto-oncogene receptor tyrosine 
kinase (MET), and B-Raf proto-oncogene serine/threonine kinase (BRAF) genes have 
been FDA approved and used as personalized second line (after chemo) therapies in 
patients harboring these specific mutations. Despite this advancement, the use of these 
drugs has only been associated with a 1.5 year average increase in survival [5].  
This is because no drug has thus far been found that is immune to the 
development of resistance. Due to cancer’s genetic instability and composition of a 
heterogeneous population of cells, new mutations are able to arise in response to 
treatments allowing cells containing them to continue to grow and expand [6].  One 
specific cell population in the heterogeneous tumor has increasingly come into focus as 
the cells responsible for drug resistance and tumor recurrence in patients following 
treatment; the cancer stem cells (CSC). CSCs possess unique properties derived from 
their genetic and epi-genetic make-up that allow them to both escape treatment and 
initiate tumors. There is a great unmet need to develop novel treatments specifically 
targeting CSCs in order to overcome drug resistance and prevent patient relapse.  
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2.2 Definition and History of CSCs 
CSCs have been characterized, ultimately, as a type of cell with the ability to initiate the 
growth of a tumor. They were originally discovered in acute myeloid leukemia (AML) 
patients via this tumor initiation property in 1994 by Lapidot et al. and tumor initiation 
ability remains the “gold standard” for verification of putative CSC populations to the 
present day. They are further defined as having two key attributes; self-renewal, and 
differentiation (Figure 1). This means that they can both divide symmetrically to produce 
more CSCs as well as asymmetrically to produce the non-stem cells that make up the 
bulk of the tumor. As shown in Figure 1, this mechanism allows CSCs that survive 
treatment to re-populate tumors with differentiated non-CSCs.  
 
Figure 1. Role of CSC in the Tumor Microenvironment 
 Model of the mechanism by which CSC can mediate the re-growth of tumors 
following treatment through their self-renewal and differentiation properties. 
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These properties were also identified by the initial studies in AML as only cells 
possessing certain markers (CD34+ CD38-) were found to be able to self-renew and 
thereby establish cancer in mice [7]. When these populations were later isolated from 
the mice and examined they were found to contain a mixture of CD34+CD38- and 
CD34+ CD38+ revealing the CSC’s ability to differentiate. These studies also 
highlighted the rarity of CSCs within the total population of cancer cells. They were 
found to represent about 1 in every 250,000 cells in patient samples. Although this 
description of CSCs in AML was groundbreaking, it was not altogether unbelievable 
since AML is a cancer arising in hematopoietic stem cells, so it follows that some 
cellular mechanisms for self-renewal and pluripotency could be dysregulated or re-
activated in this cancer. 
     On the other hand, the case for the role of CSCs in solid tumors, especially those of 
epithelial origin was not so easily made. First, simply finding stem-like cells within 
tumors does not equate to finding CSCs since it is known that mesenchymal stem cells 
(MSCs) hone to tumors and  play an important role in the microenvironment by 
supporting tumor growth [8, 9]. Tumor infiltrating MSCs were implicated in supporting 
the growth of CSCs as well [10, 11]. Unlike CSCs, MSCs do not have the ability to 
initiate tumors on their own. Secondly, the lack of any universal marker for CSCs 
caused much debate among researchers as to whether specific cells isolated by any 
one group were truly CSCs. This challenge was compounded by the fact that many 
different models were used which sometimes gave inconsistent results. Doubt was even 
cast on the “gold standard” of CSC verification, tumor initiation in mouse models, due to 
the fact that experimental factors such as enzymatic digestion protocols, growth factor 
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stimulation, and differences in genetic background of mice strains made results difficult 
to replicate between groups [12, 13].   
     Over the years, however, evidence has continued to accumulate for the tumor-
initiating role of cancer cells with stem like properties within many solid tumors. One key 
piece of evidence is the use of lineage tracing experiments to overcome the limitations 
inherent to xenograft tumor initiation models, thus revealing how single cells possessing 
a functional marker such as leucine-rich repeat-containing G-protein coupled receptor 
(Lgr5) can expand to create a large proportion of the resulting tumor [14]. Genetic 
lineage tracing also allows for the observation of expansion of cell populations in situ 
without disturbance by linking recombinase-reporter constructs to a marker gene of 
interest such that all daughter cells arising from a single parent will express the same 
reporter. While xenograft tumor initiation experiments had previously revealed that 
CSCs were more likely to be found in sub-populations expressing certain markers, 
lineage tracing has allowed researchers to pinpoint specific CSC cells and observe their 
clonal expansion as they grow within tumors [14-16].  
These experiments have added convincing support for the role CSCs play in the 
growth of solid tumors, but they are also currently revealing new insights into CSC 
plasticity and the dynamics of cell populations within tumors. They have found that 
clonal expansion of cancer cells varies depending on cancer type, stage, and treatment. 
Showing that in some cases dominant clones arise that out compete others to 
eventually compose the bulk of the tumor in a steep hierarchy where small numbers of 
dividing CSCs feeds the bulk differentiated tumor (Figure 2). In other cases (such as 
melanoma) many cells within the tumor have the self-renewing property needed to 
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proliferate resulting in a tumor with less hierarchy and much more genetic diversity 
(Figure 2) [14, 17, 18].  Evidence for CSC plasticity arises from studies of targeted 
destruction of cells with CSC markers (Lgr5) and the observation that cells previously 
thought to be differentiated were able to re-gain expression of CSC markers and the 
ability to self-renew [15, 19, 20]. Wnt/β-catenin signaling has been implicated in this 
process but much work remains to be done [21]. 
 
 
Figure 2. Proliferation and Differentiation of CSCs Create a Hierarchy of 
Lineages Within Tumors 
Application of the CSC model reveals differences in hierarchical organization of 
tumor cell populations which can vary depending on cancer type. 
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2.3     CSCs Clinical Relevance  
CSCs have shown to be resistant to drug treatments and cause patients to relapse by 
initiating the growth of new tumors, so an understanding of CSC development and 
expansion is critical to understanding drug resistance and metastasis. For these 
reasons, treatments targeting CSCs remain a highly sought after yet elusive goal. CSC 
populations have thus far been characterized in patient tumors of nearly all cancer 
types, each with their own sets of identifying biomarkers. These include lung, breast, 
liver, colon, prostate, bladder, glioma, leukemia, and melanoma among others [22-24]. 
Examples of markers that have been used to identify CSCs directly in patient samples 
include aldehyde dehydrogenase (ALDH)+ and CD133+ cells in NSCLC, CD44+/24- 
and ALDH+ cells in breast cancer, CD34+/38- in AML, and CD26+ and Lgr5+ cells in 
colon cancer [20, 25-29].  
In the current clinical environment where treatments to target CSCs are still in 
development, these CSC markers have been successfully used as prognostic markers 
to evaluate a patient’s disease and their response to treatment [26, 29, 30]. The 
success of these molecules as prognostic markers further highlights the need for CSC 
targeted therapies. Clinicians have found, independent of the underlying CSC 
hypothesis, that patient’s whose tumors contain more CSC markers tend to have poor 
outcomes and when CSC markers are lower patients have better outcomes. 
 
2.4      Properties and Identification of CSCs 
In recent years, evidence has been steadily accumulating in support of the roles 
CSCs play in tumor growth, metastasis, epithelial to mesenchymal transition (EMT), and 
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drug resistance [23, 31-35]. CSCs have been found to be resistant to drug treatment 
either by reduced metabolic activity/entry into a non-dividing quiescent state which 
confers resistance to genotoxic chemotherapy or by increased activity of drug efflux and 
breakdown pathways [34, 36, 37]. In addition, CSCs have frequently been associated 
with EMT that occurs as a precursor to metastasis leading them to also be found as 
circulating tumor cells [26, 31, 36, 38, 39].  A common marker for CSCs with a role in 
metastasis is C-X-C chemokine receptor type 4 (CXCR4). Its expression allows cells to 
migrate toward its ligand, CXCL-12, which is produced by bone marrow stromal cells 
among others and is commonly associated with metastasis to bone [40-42].   
A universal biomarker for CSCs has yet to be discovered, however several cell 
surface markers, as well as functional assays, have been accepted as biomarkers for 
CSCs both in vitro and in vivo. For example, CD133 expression and the activity of the 
drug efflux pump ABCG2, as determined by side population assay, have become 
popular CSC markers in lung cancer, CD44+/CD24- cells are generally accepted as 
CSCs in breast cancer [28, 31, 43-46]. In addition, enrichment of CSCs can be shown 
by an increase in the expression of classical stem cell related transcription factors 
(Sox2, Oct4, and Nanog) conferring self-renewal and pluripotency [40, 47-49]. Activity of 
the ALDH enzyme, which is also active in normal adult stem cells, has been used to 
identify CSCs in multiple cancer types including breast, lung, and melanoma [25, 50-
53]. Despite the identification of these markers, the study of CSCs has been limited by 
their rare occurrence in tumors, which can be as little as 0.05-1.5% [54, 55].   
Because no universal marker exists, the “gold standard” for identification of CSC 
enrichment currently remains their ability to initiate xenograft tumors in mice at very low 
11 
 
dilutions [23, 56]. Even this assay is not without its limitations, as tumor initiation ability 
has been shown to vary with the genetic background of the mouse used, in addition to 
the fact that most models using human tumor explants lack the immune component of 
the tumor stroma. Nevertheless, in vivo tumor initiation is ultimately able to identify the 
presence of CSCs in a given cell population through their ability to form a tumor where 
non-CSCs are not able to do so.  
 
2.5      Drugs Targeting CSCs 
Many strategies have been used to try and target CSCs. Some such examples are 
targeting developmental pathways (Wnt, Notch, hedgehog) that are re-activated in 
CSCs with novel chemical inhibitors, targeting the oxidative/glycolytic metabolism that 
CSCs use for energy generation, and targeting stromal components that stimulate CSC 
growth such as cancer associated fibroblasts’ release of TGFβ or tumor associated 
macrophages [23, 57-59]. However, none of these strategies have been translated into 
a successful clinical treatment, although they are still being actively pursued.  
Despite numerous clinical trials, many of the novel agents targeting 
developmental pathways fail as drugs because they are toxic to the normal adult stem 
cells that rely on these pathways and that are required for basic bodily functions [60]. In 
addition, because these pathways often contain complex regulatory mechanisms and 
redundancies it is unlikely that any single agent will ultimately be effective in targeting 
CSCs. Cancer cells will continue to develop new mutations and gene expression 
patterns to route around the particular signaling molecule that is inhibited. Therefore, 
interest is shifting towards combination therapies.  
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Through their ability to target multiple pathways or multiple elements of the same 
pathway simultaneously, combination therapies may prevent any single new mutation 
that arises from conferring drug resistance. This leads to the present challenge of 
finding drug combinations that are effective in targeting CSCs without being overly toxic 
to healthy cells. While work remains ongoing, the development of improved in vitro and 
in vivo models (such as the 3D scaffold presented herein) to facilitate drug screening 
will be vital in the search for effective combination therapies. 
 
2.6      Concluding Remarks 
     In conclusion, sufficient evidence has accumulated not only for the existence of 
CSCs in solid tumors but also their critical roles in tumor growth, drug resistance, and 
metastasis. Therefore, the development of novel therapies to target CSCs holds great 
promise to improve patient outcomes. To efficiently study CSCs, novel in vitro models 
are desperately needed to overcome the fact that CSCs make up a very small fraction 
of cancer cells. Furthermore, the molecular mechanisms driving their expansion remain 
incompletely understood. We hypothesize that a fibrous scaffold 3D culture environment 
will promote CSC expansion through enhanced cell-cell and cell-matrix interactions 
creating a more representative model of CSC growth by eliminating artificially 
introduced reprogramming factors and growth factors. We further hypothesize that drug 
treatments targeting CSCs can be identified using this in vitro model. They will also be 
more effective in reducing tumor burden than traditional chemotherapies and targeted 
therapies through elimination of the self-renewing cell population that drives tumor 
growth and the development of drug resistance.  
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CHAPTER 3 
GENERAL METHODS 
 
This section presents the general molecular biology techniques used during the study.  
 
In vitro Studies: 
3.1  Assay for Reactive Oxygen Species 
To assay for the production of reactive oxygen species (ROS) Cells were plated in 
monolayer culture 24hr prior to treatment. LLC1 cells were treated with 0.4nM 
Actinomycin D, 1µM Telmisartan, or the combination for 48hr prior to staining. The dye 
CM-H2DCFDA was used according to manufacturer’s instructions. Briefly, cells were 
stained in PBS containing 5µM CM-H2DCFDA at 37°C for 20 minutes. Following 
staining cells were washed in PBS. Staining was assayed immediately using 
fluorescence microscopy with a GFP filter. Bright field images were also acquired for 
reference. Staining was also assayed by flow cytometry (BD FACS Canto/Diva). 
 
3.2 Beta Catenin Activity Assay 
 Active β-catenin was assayed in monolayer and 3D cultures using a Cignal TCF/ 
Luciferase reporter system (Qiagen). Cells were transfected with the control or reporter 
plasmid using Lipofectamine 3000 reagent on day 3 of 3D culture (Thermo Scientific) 
and treated with drugs at stated concentrations 48 hours after transfection. Luciferase 
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activity (firefly reporter and renilla transfection normalization control) was assayed using 
the Dual Glo luciferase assay (Promega) in a BioTek Synergy H4 plate reader after 48 
hours of treatment.   
 
3.3 Cell culture 
Polymeric nanofiber scaffold was prepared as previously described [61]. Briefly, a 
chloroform/dichloromethane solution containing mPEG-PLA and PLGA polymers was 
electrospun using a spraybase instrument at 20kV at a flow rate of 0.5mL per hour to 
create the sheet of randomly aligned fibers. Scaffolds were sterilized in ethanol, washed 
three times with PBS, additionally sterilized under UV light for 45 minutes, and then 
washed in cell culture media. Cells were seeded onto scaffolds in appropriate culture 
media (DMEM or RPMI containing 10%FBS and 1% penicillin/streptomycin) in standard 
cell culture well plates. Cell lines were obtained from the American type culture 
collection (ATCC). Drug tolerant H1975 were created by continuous exposure to 
Lapatinib in culture at a concentration of 7.5µM for 20 days. IC50 values for Lapatinib of 
parental H1975 and drug tolerant H1975 were compared to verify drug tolerance using 
the CellTiter-Glo. Cells were cultured in a humidified incubator at 37⁰C in a 5% CO2 
atmosphere (Thermo Fisher). 3D Tumoroid formation was assessed using fluorescent 
microscopy (Olympus BX51) after nuclear staining with Nuc Blue dye (Thermo 
Scientific).  
 
 
 
15 
 
3.4 CRISPR/Cas9 
Plasmids containing CRRISPR/Cas9 constructs as well as scrambled control were 
purchased from Genecoepia. Cells were transfected using Lipofectamine 3000 
according to manufactuer’s instructions. Transfected cells were selected using 5µg/mL 
puromycin and plated at a concentration of 100 cells/mL to obtain colonies composed of 
individual clones. These colonies were expanded in culture for downstream 
experiments. 
 
3.5 CXCR4 Promotor Activity Assay 
LLC1 cells were transfected using lipofectamine with a CXCR4 promoter reporter 
plasmid (MPRM14968-PG04, Genecopia) (1391 bp) containing a luciferase gene as 
reporter for CXCR4 activity and a secreted alkaline phosphatase gene as a control for 
transfection. Luciferase activity was assayed in the presence or absence of NPRA 
inhibitor using a luciferase based promotor reporter assay (Gluc-ON). Results were 
normalized for transfection efficiency using secreted alkaline phosphatase control and 
the Secrete-Pair assay kit (Genecoepia) Cells were stimulated with 1μg/mL 
lipopolysaccharide (LPS) and treated with 40μM Anantin.  
 
3.6 Flow cytometry  
All flow cytometry experiments were performed using a Becton Dickenson (BD) FACS 
Canto II system at the University of South Florida COM Fred Wright Jr Flow Cytometry 
Core. Cell sorting was performed on a BD FACS Aria system at the Flow Cytometry 
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Core at the H. Lee Moffitt Cancer Center & Research Institute. ALDH assays were 
performed using the ALDEFlour kit (Stem Cell Technologies) according to manufactures 
instructions. Controls Treated with Diethylaminobenzaldehyde (DAEB) were used to 
distinguish ALDH positive cells from background fluorescence. Antibody staining to 
determine CD44 and CD24 expression was performed using FITC or APC-Cy7 
conjugated anti-CD44 and  Alexa 647 conjugated anti-CD24 from BD. Cells were 
stained on ice for 25 minutes in FACS buffer consisting of PBS containing 5% FBS and 
1mM EDTA. Dead cells were identified and excluded using 4′,6-diamidino-2-
phenylindole (DAPI) staining. Analysis was done in BD FACS Diva software.  
 
3.7 IC50 Assay 
IC50 of drug treatments in 3D or monolayer culture was determined by Cell Titer Glo 
Assay (Promega) Culture media was changed to media containing drug dilutions on day 
4 of culture and viability assay was performed after 48 hours on day 6 of culture. Cell 
Titer Glo reagent was added and incubated according to manufacturers’ instructions 
and luminescence was measured in a white well-plate in a Bio-Tek Synergy H4 plate 
reader. Actinomycin D was obtained from Acros Organics and Telmisartan was 
obtained from Selleckchem. Dose response curves were plotted and IC50 values were 
estimated using Graph Pad Prism software. 
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3.8 Immunofluorescence Staining  
Immunocytochemistry for Nos2 (Cell Signaling #D6B6S) was performed on LLC1 
tumoroids cultured for 6 days on scaffold. Tumoroids were fixed and permeablized on 
scaffold prior to staining. 
 
3.9 Magnetic Cell Separation 
CD24 expressing cells were depleted from A549 cell cultures using magnetic cell 
separation columns and CD24 antibody conjugated magnetic beads (Miltenyi Biotech) 
according to manufactures’ instructions. Depletion was verified using flow cytometry as 
stated above. 
 
3.10 qPCR Array 
Gene expression analysis was performed on LLC1 3D cultures using the cancer stem 
cell RT2 PCR profiler array (Qiagen). RNA was isolated as stated above and processed 
according to manufactures’’ instructions. Array plates were read in a Bio Rad CFX-384 
thermocycler and analysis was performed using the Qiagen Gene Globe Data Analysis 
Center web application. 
 
3.11 Quantitative Reverse Transcriptase PCR 
Total RNA was isolated from tissues or cell pellets using RNeasy columns (Qiagen) 
cDNA synthesis was performed using the Maxima cDNA synthesis kit (Thermo 
Scientific) according to manufacturer protocol. Real time analysis was performed using 
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a SYBR Green assay (Genecoepia) in a Bio Rad CFX-384 thermocycler using primers 
obtained from Integrated DNA Technologies. (See Table 1 for primer sequences). Data 
analysis was performed in Bio Rad CFX Maestro software with a significance threshold 
of p≤0.05. 
 
3.12 Transcriptome Profiling Using RNA Quantification Sequencing  
Transcriptome Profiling by RNA-Seq was performed by our collaborator Dr. 
Manoj Bhasin. RNA derived from LLC1 tumors was subjected to next-generation 
sequencing (NGS) to generate deep coverage RNASeq data. For each treatment group, 
sequencing was performed on 2 biological replicates. Sequencing libraries of Poly A 
selected mRNA were generated from the double-stranded cDNA using the Illumina 
TruSeq kit according to the manufacturer's protocol. Library quality control was checked 
using the Agilent DNA High Sensitivity Chip and qRT-PCR. High quality libraries were 
sequenced on an Illumina HiSeq 2000. To achieve comprehensive coverage for each 
sample, we generated ~20-25 million paired end reads for each sample.  
 
RNASEQ data analysis:  
The Raw sequencing data was processed to remove any adaptor, PCR primers 
and low quality transcripts using FASTQC and fastx/cutadapt. These provide a very 
comprehensive estimate of sample quality on the basis of read quality, read length, GC 
content, uncalled based, ratio of bases called, sequence duplication, adaptor and PCR 
primer contamination. These high quality, clean reads were aligned against human 
genome using hisat2. We used GRch38 human genome assembly as reference 
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genome for alignment. Gene expression measurement was performed from aligned 
reads by counting the unique reads using featureCounts algorithm. The read count 
based gene expression data was normalized on the basis of library complexity and 
gene variation. The normalized count data was compared among groups in paired 
manner using limma models to identify differentially expressed genes. The differentially 
expressed genes were identified on the basis of raw P value and fold change.  Genes 
were considered significantly differentially expressed if the multiple text corrected p-
value was <.05 and absolute fold change >2. 
Functions, Pathway and regulatory network analysis 
Ingenuity Pathway Analysis (IPA, Qiagen) was used to identify the pathways that are 
significantly affected by significantly differentially expressed genes. The knowledge 
base of this software consists of functions, pathways and network models derived by 
systematically exploring the peer reviewed scientific literature. A detailed description of 
IPA analysis is available at the Ingenuity Systems’ web site (http//www.ingenuity.com). 
It calculates a p-value for each pathway according to the fit of users’ data to the IPA 
database using one-tailed Fisher exact test. The pathways with p-values <0.05 were 
considered significantly affected. Further systems biology analysis was performed using 
upstream regulators enrichment approach to identify upstream transcriptional regulators 
that can explain observed transcriptome changes. Regulatory analysis help in 
identifying significantly activated or inhibited transcriptional regulators on the basis of 
upregulation or downregulation of its target genes.The significance of transcriptional 
regulators activation/inhibition was determined using one-tailed Fisher‘s Exact test. The 
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regulators with a P value <.01 and absolute Z-score  2 were considered statistically 
significant. 
 
3.13 Sphere Formation Assay 
Sphere efficiency was determined using sphere formation assays. Sphere media was 
prepared as previously described [62]. Cells were plated at a density of 2 cells per µL in 
sphere media in low attachment plates (Corning). Drugs were added 24 hours after cell 
plating and spheres were imaged using bright field microscopy after 6 days of culture. 
Sphere size and diameter was measured using ImageJ software statistical analysis was 
performed in Graph Pad Prism software. Sphere efficiency is represented as the 
percentage of cells seeded that were able to proliferate under low attachment conditions 
and defined as the number of spheres counted at endpoint divided by the number of 
cells seeded times 100. 
 
3.14 Western immunoassay 
Immunoassays for relative protein abundance were performed using Wes according to 
manufacture instructions (Protein Simple) Total protein was isolated using RIPA buffer 
and protein concentration was determined by Bradford assay. Caspase3 (Cell Signaling 
#9662p) PARP (Cell Signaling #9542) β-actin (Sigma #A2228). 
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3.15 Wnt Pathway Phospho-Antibody Array 
LLC1 subcutaneous flank tumors were treated and collected as described above. 
Tumors from each treatment group were snap frozen on dry ice and stored at -80C. 
Protein was isolated using an antibody array assay kit (Full Moon Biosystems) and 
loaded onto Wnt phospho explorer array slides (Full Moon Biosystems) per 
manufactures’ instructions.    
 
In Vivo Studies: 
3.16 Animal Experiments 
C57/Bl6 mice were purchased from Envigo and NSG immunocompromised mice 
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) were purchased from Jackson Laboratory. 
Subcutaneous tumors were grown in the flanks of mice by injecting one million LLC1 
monolayer cells, 100,000 LLC1 3D cultured cells, or 5 million A549 cells. Tumors were 
allowed to grow and treatment was started when they became palpable (2-3mm 
diameter). Drugs were injected intratumorally once every 3 days at the concentrations 
treated with 50µg/kg Actinomycin D (AD), 1mg/kg telmisartan (TS), or combination. 
Drug solutions were made in PBS with 1%DMSO and this solution was used as vehicle 
control. Tumors were collected when controls reached 10mm in diameter. To obtain 
single cell suspensions of tumors the tissue was digested using a mouse tumor 
digestion kit and Gentle MACS instrument (Miltenyi Biotech) according to manufacturer 
instructions. Animals were housed in the University of South Florida comparative 
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medicine facility at the Morsani College of Medicine and all protocols were reviewed and 
approved by the USF institutional animal care and use committee.  
 
General Statistics: 
3.17 Statistics    
 Experiments have been repeated at least twice. Statistical significance for each 
experiment was determined using Analysis of variance (ANOVA) and the Tukey post 
hoc test, p<0.05. Calculations were performed and graphs plotted using Prism 6.0 
software (Graphpad Software, San Diego, CA, USA). Graphs of results show the mean 
and error bars depict the average, +/- standard deviation. 
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Table 1. Primer Sequences used for Quantitative Real Time PCR 
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CHAPTER 4 
Culturing Cancer Cells on the 3D Scaffold Increases Their Stemness 
 
4.1 Introduction 
Metastatic and drug resistant cancers are responsible for the vast majority of cancer-
associated morbidity and mortality[24, 63]. Therefore, novel strategies to target these 
aggressive forms of the disease are desperately needed. CSCs, which comprise a 
minority (<1%) of the population of cells within tumors, possess self-renewal and multi 
lineage differentiation potential and are thought to be responsible for drug resistance in 
cancers. CSCs can be identified using several methods including the use of surface 
markers, expression of transcription factors, and functional assays. However, the 
populations identified by these methods can vary greatly among the types of 
experimental model used and may or may not represent distinct cell phenotypes[64-70]. 
It has been suggested that the tumor microenvironment (TME) plays a pivotal role in 
CSC proliferation, differentiation, and contributes to development of drug resistance. 
However, the precise cellular and molecular mechanisms responsible remain to be 
elucidated and the development of an adequate in vitro model for such analyses 
remains a critical unmet need. To this end, the broad long-term goal of this project is to 
develop an in vitro model replicating in vivo tumor matrix and cell-cell interaction that 
promotes proliferation of the CSC population. Then to use this model first, to investigate 
the molecular mechanisms responsible for the expansion of drug resistant and 
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metastatic CSCs, and secondly to identify a novel therapeutic combination treatment to 
target CSC. 
This work is based on past developments in our lab. A 3D polymeric nanofiber 
scaffold as a substrate for cell growth was developed, which provides structural support 
to the cells partially replicating the function of extracellular matrix [61]. The scaffold 
developed in our lab is an electrospun mat of fibers consisting of a mixture of two 
polymers; methoxy-polyethylene-glycol(poly lactic acid) copolymer and polylactic-co-
glycolic-acid.  Previous studies from our Lab indicate that cells cultured on the scaffold 
exhibit some altered phenotype compared to cells grown as a monolayer resulting in 
increased resistance to anti-cancer drugs as well as increased expression of EMT 
markers; two important traits of CSCs [61]. This scaffold functions to increase cell-cell 
and cell-matrix interactions compared to 2D culture, thus resulting in the growth of 3D 
tumor organoids referred to as “tumoroids”. The availability of this system has led to the 
following hypotheses: (i) When cells are cultured on the scaffold their expression of 
genes and proteins are expected to be altered to a profile more similar to that found 
within primary tumors where CSCs develop. Profiling of the molecular changes that take 
place when cells are cultured on scaffold could lead to insight into the mechanism by 
which CSCs develop in vivo and identify new chemotherapy targets for CSCs. (ii) This 
3D culture system may serve as a platform to enrich rare CSC population for 
downstream mechanistic studies of the factors influencing CSC development and for 
drug screening. Therefore, this 3D tumoroid model will be used to study and further 
define the mechanisms by which CSC proliferate and their population expands. We are 
proposing to expand the CSC population in culture and identify the molecular 
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mechanisms responsible for this expansion. To accomplish this, we will determine 
changes in cell phenotype that are caused by culture on 3D scaffold and whether these 
changes represent an enrichment of CSCs.  Mouse and human lung cancer cell lines 
will be tested for changes in multiple markers and functional assays, including 
expression of transcription factors and stem cell surface markers. We will determine 
whether these changes represent an enrichment of CSCs by testing for known CSC 
cellular functions and confirm these results in a mouse model where putative CSCs will 
be tested for enhanced tumor initiation.  
3D cultures provide significant advantages over 2D to study CSCs. The 
significance of the role of CSC populations in disease progression is becoming 
increasingly recognized by researchers. However, the characteristics of CSCs remain 
poorly defined  [11-14]. CSCs identified by different methods have been found to 
behave in different ways and conflicting reports have been published claiming that the 
various identification methods do or do not identify a common population [1, 4, 15]. 
Many of these studies have been carried out in a 2D culture environment or in 
suspension culture where no extracellular matrix or other stromal environment is 
present [15-18]. Cells grown in these types of culture environments will adapt to the 
foreign conditions by altering their gene expression, therefore becoming less 
representative of in vivo tumors and less relevant models of disease [19, 20]. The fact 
that CSCs can make up as little as a fraction of one percent of the total cells grown in 
2D cultures means they are difficult to isolate and even more difficult to maintain in 
culture once isolated. In order to more effectively study CSC populations, a culture 
environment that supports their growth and development is needed. To overcome the 
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fact that CSCs are such a small percentage of the tumor population, methods have 
been developed to expand CSCs in culture so they can be studied without interference 
from the differentiated cells that make up the bulk of tumors. These include artificial 
manipulations such as transforming cells with classical stem cell transcription factors 
(Sox2, Oct-4, c-Myc) or by exposing them to growth factors known to induce EMT 
(Wnt5a, TGFβ), as well as by changes to the structure of the culture environment such 
as hanging drop, suspension culture, or growth on hydrogels with or without 
extracellular matrix components [39, 71-74].  
Of these, the most commonly used is suspension culture where anoikis resistant 
cells are grown into floating “tumorspheres” in the presence of the growth factors 
epidermal growth factor (EGF) and fibroblast growth factor (FGF) [62, 75, 76]. This has 
been shown to increase CSC marker expression and traits in functional assays. The 
ability for cells to survive in the absence of attachment is an indicator of the latent CSC 
potential within a given parental population. However, this technique has 
disadvantages, including the low CSC number obtained and re-differentiation once cells 
are removed from the growth factor containing tumorsphere media [22].  
     Synthetic culture substrates such as microspheres or fibers made from poly-
caprolactone or poly-lactic co-glycolic acid have been used although much less 
frequently [61, 74]. These have the advantages of large surface area for cell growth as 
well as porosity to oxygen and nutrients, which have shown (by our lab as well as other 
groups) the ability to induce EMT and increase expression of stem cell transcription 
factors. Finally, CSCs have been directly isolated from in vivo tumors (either patient or 
mouse model) through methods such as fluorescent or magnetic cell separation based 
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on CSC marker molecules, but these methods have a high cost and result in low 
numbers of CSCs obtained [22]. It is these advantages and published results that have 
motivated the present work developing, studying, and validating a synthetic 3D scaffold 
model for CSC expansion and CSC targeted drug screening.   
The majority of work in the 3D cell culture field is currently focused on hydrogels 
or matrigel [11-15]. While these are important and useful advances, this type of material 
does have some drawbacks that we aim to overcome through the development of a 
fibrous scaffold environment.  Gels are relatively permeable to solutes, but fibrous 
scaffolds are inherently more permeable allowing for better diffusion of nutrients and 
growth factors. Many gels have components of biological origin which can induce batch 
variation and create a complex environment that is not strictly defined [16]. Gels are 
also uniform in structure, whereas fibrous scaffolds can be designed with different pore 
sizes and fiber diameters to create micro structures for cells to interact with. The 
contribution of a 3D fibrous scaffold culture environment is significant because it will 
provide an in vitro platform to study CSC origin, development, and cell-cell interactions. 
It will also reveal the mechanisms by which the structure of the extracellular 
environment can influence CSC proliferation. 
CSCs have been identified in most types of cancer including breast, prostate, 
renal, colon, pancreas, and lung [77-80]. However, they have only been extensively 
studied in breast cancer models and even within that narrow field controversy still exists 
regarding the optimal method to identify the population and whether the diverse 
methods available identify a common population [64, 81]. The work presented here is 
innovative, because we aim to generate a novel 3D culture system for CSC enrichment 
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and use it to determine the factors and signals that contribute to CSC proliferation. This 
work will allow CSC populations isolated by different methods to be cultured and studied 
more easily, thus leading to better characterizations and refinement of in vitro cancer 
models, as well as identification of drug targets to limit CSC development in vivo. 
In lung cancer, the five year survival rate is less than 10-20% for NSCLC and 5% 
for SCLC [82]. This is due to the high rates of metastasis and drug resistance [83, 84]. 
The CSC population in lung cancer, which is likely responsible for these traits, has not 
yet been definitively characterized. A 3D fibrous scaffold material has been chosen to 
study this population because of the advantages it offers over traditional monolayer 
culture and mouse models [85]. Because monolayer cultures lack the 3D structure of 
the ECM, cell behavior is altered and therefore results generated do not reliably 
translate to the clinic [86, 87].  Humanized mouse models do a better job of 
recapitulating in vivo human cell behavior but they are very expensive and can be more 
difficult to work with. For example, removing a single cell type from tumors or creating 
cell type specific knockouts is very time consuming and technically challenging [86, 88]. 
The scaffold culture model will be easier to manipulate in a controlled in vitro 
environment while still providing the 3D structural complexity to replicate the in vivo 
environment. When cells are cultured on the scaffold they grow as “tumoroids”. We 
have also found that cancer cells cultured on the scaffold exhibit enhanced resistance to 
multiple anti-cancer drugs and increased expression of some CSC markers.[85].  
However, the extent of these phenotypic changes is unknown. 
      We hypothesize that expansion of the CSC population plays a central role in drug 
resistance and metastasis. We further hypothesize that culture on the scaffold will lead 
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to an enrichment of CSCs with enhanced proliferative and metastatic properties. The 
enriched CSCs within cell lines will be identified by increased expression of CSC 
markers, as well as increased tumor initiation ability in vivo. These hypotheses will be 
tested using the 3D platform developed in our lab that has the potential to enrich the 
populations of metastatic and drug resistant CSCs in lung cancer cell lines. The first 
step towards identification of a true population of lung CSCs is to determine what 
molecular changes take place when cells are cultured on the scaffold. We aim to more 
fully characterize the phenotypic changes that occur when human lung cancer cells and 
biopsies of subcutaneous murine tumors are cultured on the scaffold. Lung cancer cell 
lines containing mutations in their epidermal growth factor receptor (H1975 and H460) 
and also KRAS (H460) will be used in addition to EGFR wild type cell lines 
human(A549) and mouse (Lewis lung carcinoma 1 (LLC1)) to represent a range of 
NSCLCs with differing growth characteristics and tendencies to develop drug 
resistance. Mutation status of the cell lines used is summarized in Table 2.  
 
Table 2. Table of Cell Lines Used and Their Mutation Status in Key Tumor 
Promotor/suppressor Genes 
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     It is expected that culture of lung cancer cells on scaffold will cause significant 
changes to cell morphology and phenotype compared to monolayer culture. The study 
of altered gene expression seen in scaffold culture is expected to help identify key 
signaling cues that support CSC proliferation. This will provide new insights into the 
mechanism by which CSCs develop in vivo, as well as a platform for future studies on 
isolated or enriched CSCs. Our lab is uniquely positioned to carry out this research 
because we have previously developed the 3D fibrous scaffold that we will use for cell 
culture. We also have expertise working with the required experimental protocols and 
tools, support from the USF flow cytometry core, and extensive experience working with 
mouse models of lung and prostate cancer. Upon completion of this project, we will 
achieve a better understanding of the similarities and differences in CSC composition 
Figure 3. Model of CSC Enrichment by 3D Tumoroid Culture 
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and behavior in different cell lines, as well as tumor biopsies. We will gain new insight 
into the signals that influence CSC propagation, which may be useful in identification of 
drug targets. We will have created and validated a novel culture environment that 
promotes the growth of CSCs to be used in future studies.  
 
4.2      Results 
     To establish the tumoroid model of cancer cell growth on our 3D scaffold material we 
began by ensuring that mouse and human lung cancer cell lines would form tumoroids 
when cultured on the scaffold. First, the properties of the 3D material (fiber diameter, 
porosity, uniformity of fibers) was confirmed to be consistent with batches used in 
previous work by scanning electron microscopy. (Figure 4A) Once the production of 
uniform material was confirmed, mouse (LLC1) and human (H1975, A549, H460, and 
H1299) cell lines were seeded onto the scaffold in cell culture media and imaged using 
fluorescent microscopy after 6 days of culture to assess tumoroid formation. (Figure 4B-
F)   
     In figure 4B, LLC1 were stained with the cell membrane stain, Calcein AM (green), 
and in figure 4 C-F human cell lines were stained with the nuclear stain, NucBlue (blue). 
In all cell lines, 3D tumoroids in scaffold cultures were roughly 50-200µm in diameter on 
day 6 of culture. To determine whether cells cultured as 3D tumoroids acquired CSC 
properties we collected tumoroids from LLC1 and A549 cultures on day 6 and assayed 
their expression of CSC related genes compared to monolayer culture using 
quantitative real time PCR. (Figure 5) In LLC1 tumoroids we found the stemness 
transcription factors Sox2, Oct4, and Nanog to be elevated along with the aldehyde 
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dehydrogenase gene, aldh1a1. In A549 tumoroids we also found expression of Sox2 
and Nanog to be elevated along with the CSC surface marker CD44, although only the 
increase in CD44 was statistically significant.  
 
 
Figure 4. Lung Cancer Cell Lines Cultured on 3D Scaffold form   
Tumoroids 
 
A. Scanning electron micrograph depicting fibrous structure of the 3D 
scaffold. 
B. LLC1 cells grown as tumoroids on the 3D scaffold for 6 days stained 
with the membrane stain calcein AM (green) 
C-F. Human NSCLC cell lines grown as tumoroids on the 3D scaffold for 
6 days stained with the nuclear stain NucBlue. 
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In addition to cell line derived tumoroids we have previously described the utility 
of the 3D scaffold to culture biopsy derived tumoroids [61]. This method has the 
advantage of including stromal cells such as cancer associated fibroblasts and myeloid 
derived suppressor cells in the tumoroids, which is a more accurate representation of 
the in vivo tumor/stroma microenvironment. Using the mouse LLC1 cell line, which is 
syngeneic to the C57 BL/6 mouse strain, facilitates the collection of biopsies from 
subcutaneous tumors. Fine needle aspirate biopsies were collected from LLC1 tumors 
Figure 5. Expression of CSC Marker Genes is Increased in Lung Tumoroid 
Culture 
LLC1 or A549 cells were cultured as monolayer or on scaffold for 6 days. RNA 
was isolated using affinity column (Qiagen), and cancer stem cell marker gene 
expression in monolayer vs scaffold cultures was assayed by qPCR. N=3 
*p≤0.05. 
 
35 
 
when they reached 7mm in diameter. Cells obtained from LLC1 biopsies were then 
cultured on monolayer or scaffold for six days. These cultures were subsequently fixed, 
permeabilized, and immuno-stained for their expression of Oct4 or Sox2 transcription 
factors (Figure 6). In agreement with the qPCR data in figure 6, LLC1 biopsy tumoroids 
stained more intensely for both Oct4 and Sox2 than LLC1 biopsy monolayer cells.  
 
 Due to the fact that we had observed increased CD44 expression in A549 
tumoroids by qPCR and that the CD44+/24- population is known to possess CSC 
properties in some cancers, we next assayed both A549 biopsy tumoroids and H460 
tumoroids for their expression of CD44 and CD24 by flow cytometry. A549 biopsies 
Figure 6.Expression of CSC Transcription Factors is Increased in LLC    
Biopsy Derived Tumoroids 
 Immunostaining LLC1 biopsies for stem cell transcription factors. Cells were 
cultured for 7 days either as a monolayer (A and C) or on 3D scaffold (B and D).  
Cells were stained red for Oct4 (A and B) and green for Sox2 (C and D). DAPI 
(blue) was used as a nuclear stain.  Scale bar = 100μm 
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were obtained by subcutaneous growth of tumors initiated using the A549 cell line in 
NOD SCIID gamma immunocompromised mice. A549 form a much more solid tumor 
than LLC, so needle biopsies were not practical. So, whole A549 tumors were collected 
when they reached 7mm in diameter and digested as described in the methods to 
obtain single cell suspensions. CD44 and CD24 expression was compared on freshly 
digested tumor cells and tumor cells cultured as tumoroids for 6 days. (Figure 7) The 
freshly digested tumor had a CD44+/24- population of approximately 10%, with the 
majority of cells CD44-/24-. After tumoroid culture the CD44+/24- population increased 
to almost 30% accompanied by a large increase in overall CD44 and CD24 expression, 
with the majority of cells CD44+/24+ in addition to the CD44+/24- population. 
CD44+/24- analysis was subsequently performed on H460 tumoroids compared to 
H460 monolayer with similar results. H460 monolayer was found to contain 
Figure 7. Expression of the CSC Marker (CD44+/24-) is Increased in A549 
Biopsy Derived Tumoroids 
CD44+/24- population as assayed by flow cytometry in cells collected directly 
from sub-cutaneous A549 tumors vs cells collected from A549 tumors and 
cultured as tumoroids for 6 days. 
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approximately 9% CD44+/24- cells, with the majority of cells being CD44+/24+ (Figure 
8). Tumoroid culture increased the CD44+/24- population to 33% seemingly through a 
reduction in CD24 expression. (Figure 9)  
 
Since we observed an increase in aldh1a1 expression in LLC1 tumoroids, we 
aimed to confirm this result through assays of ALDH activity in mouse and human 
tumoroids compared to monolayer culture. Figure 10A depicts ALDH activity in the 
H1975 cell line as measured by flow cytometry using the ALDEFluor kit (StemCell 
Technologies) with the ALDH inhibitor N,N-diethylaminobenzaldehyde (DEAB)  provided 
as a negative control for background auto fluorescence. We observed a 5.2% increase 
in ALDH activity in H1975 tumoroids. We also assayed ALDH activity in LLC1 tumoroids 
and found a larger 34.5% increase compared to LLC1 monolayer (Figure 9B). We 
continued to culture the LLC1 tumoroids, dissociating and re-plating the cells on fresh 
scaffolds every 6 days for three generations. By the end of the 3rd generation ALDH 
Figure 8. Expression of the CSC Marker (CD44+/24-) is Increased in H460 
Tumoroids 
H460 cells were cultured as monolayer or tumoroids for 6 days. Cells were 
collected and CD44+/24- population was assayed by flow cytometry. 
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activity had increased such that nearly 90% of cells in the tumoroids had higher activity 
than LLC1 monolayer. (Figure 9B) This effect represents a statistically significant 
increase in ALDH activity. (Figure 9C) 
Figure 9. Aldehyde Dehydrogenase Activity is Increased by Tumoroid Culture  
A. The ALDH+ population was assayed by flow cytometry using the ALDEFluor kit 
in H1975 cells cultured as monolayer or tumoroids. 
B. The ALDH+ population was assayed by flow cytometry using the ALDEFluor kit 
in LLC1 cells cultured as monolayer or tumoroids for multiple 6 day generations. 
C. Percent increase in ALDH+ cells in LLC1 tumoroids vs LLC1 monolayer. N=3 
*p≤0.05 
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      CSC markers have been shown to be increased in tumoroid culture, so we aimed to 
confirm the development of CSC properties in tumoroids using the functional assays of 
sphere formation and tumor initiation. As discussed in chapter 2, these functional 
assays are important to ensure that the CSC markers used in this model are truly 
identifying cells that can self-renew and are able to form tumors. When LLC1 tumoroids 
were dissociated and tested for their ability to form spheres under low attachment 
conditions they were found to have an increased sphere forming ability (2.8%) 
compared to cells taken from LLC1 monolayer (2.3%). (Figure 10A-B) Not all cells 
within 1st generation tumoroids were ALDH+, so the ALDH+ cells were isolated from 
tumoroid culture using FACS. The sphere efficiency of the ALDH+ population was found 
to be more than double that of monolayer culture at 4.8%. (Figure 10A-B) The sphere 
growth properties were observed to be slightly different between groups as depicted by 
Figure 10.  Sphere Formation Efficiency is Increased by Tumoroid Culture 
and ALDH Activity 
A. Sphere efficiency of LLC1 cells derived from monolayer (M), scaffold (S), or 
ALDH+ population obtained by FACS. Sphere efficiency = cells plated/ # of 
spheres observed. N=3 *p≤0.05 
B. Box plot showing size distribution and sphere efficiency % of spheres from (A).  
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changes to the size distribution of spheres (Figure 10B), with tumoroid cells growing a 
large number of small spheres while monolayer and ALDH+ cells grew a larger range of 
sphere sizes. This is most likely an indication of differences in the ability to proliferate 
but the specific mechanism causing this requires further investigation.  
 
To investigate the tumor initiation ability of the ALDH+ LLC1 and CD44+/24- 
A549 populations, these populations were isolated from tumoroids by FACS or MACS, 
respectively and used to initiate subcutaneous flank tumors in C57 BL/6 or NOD SCIID 
gamma mice. The LLC1 ALDH+ were able to initiate tumors much more efficiently than 
parental LLC1 tumoroid cells at a concentration of 10,000 cells per flank. (Figure 11A) 
Figure 11. CSC Populations Enriched by Tumoroid Culture have Enhanced 
Tumor Initiation Ability 
A. Tumor initiation ability of LLC1 CSC population. LLC1 cells cultured on 3D 
scaffold vs isolated ALDH high population were injected subcutaneously using 
10,000 cells per flank and the size of the resulting tumors was measured by 
caliper.  N=2 p=0.1 
B. Tumor initiation ability of A549. Parental cells vs MACS isolated CD44+/24- 
population were injected subcutaneously into the flanks of Nod/SCIID 
immunocompromised mice using the cell numbers indicated for each group. N=3 
*p≤0.05 
 
Day 
* 
* 
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The A549 CD44+24- cells were also able to initiate tumors more efficiently than 
parental, as CD44+/24- tumors seeded with 25,000 cells grew at a faster rate than 
parental tumors seeded with 5x106 cells and eventually surpassed the parental in size. 
(Figure 11B)   
 
Figure 12. Expression of CSC Marker Genes Changes Over Time During 
Tumoroid Culture 
A. A qPCR array was used to identify changes in RNA expression for cancer 
stem cell related genes in first, second, and third generation LLC1 scaffold 
culture. Data was normalized to LLC1 monolayer and fold change values are 
presented as a table.  
B. Scatter plot showing up and downregulated genes in LLC1 3
rd
 generation vs 
LLC1 monolayer. 
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Since LLC1 tumoroids, and especially the ALDH+ population they contain, were 
confirmed to have the key CSC properties of enhanced sphere formation and tumor 
initiation, their gene expression profile was further characterized using a qPCR array 
containing primers for genes know to be important markers and drivers of the CSC 
Figure 13. Expression of CSC Marker Genes is Enhanced by Tumoroid Culture 
in Multiple Cell Lines 
 
A. Human NSCLC cell lines A549. H1299, and H460 were cultured at 3D tumoroids 
for 6 days or as monolayer. Cell pellets were collected from each culture, RNA was 
isolated and CSC related gene expression was analyzed by qPCR. Data represents 
increase in gene expression in tumoroids as compared to monolayer. One way 
ANNOVA was used to calculate significance (Prism) N=3 *p≤0.05. 
B. Nos2 Expression in the human cell lines H1299, A549, H460 and mouse LLC1 
cultured on scaffold for 6 days normalized to monolayer.  
C. IHC staining for Nos2 protein in 1st Gen LLC1 tumoroids fixed on day 6 of culture 
and stained with rabbit anti mouse Nos2 and Alexa 488 anti-rabbit secondary. (600X 
magnification) *p≤0.05 
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phenotype. In order to better understand the mechanism by which culture on the 3D 
scaffold is able to promote the growth of CSC, samples from 1st, 2nd, and 3rd generation 
tumoroids were used to identify gene expression changes that occurred over time in 
stem cell related genes. Several genes were found to be up-regulated including Nos2, 
PLAT, and CD34. Many of these are involved in Wnt/β-catenin signaling, a pathway 
known to drive cell proliferation and regulate cell-cell adhesion in cancer. (Figure 12A) A 
scatter plot of overall gene expression changes occurring between LLC1 monolayer 
culture and 3rd generation scaffold is also provided. (Figure 12B) 
 Nos2 showed the greatest increase in scaffold culture and this result was 
replicated in the human adenocarcinoma cell lines A549, H1299, and H460 as well as in 
LLC1 when cultured on scaffold. (Figure 13A) Immunohistochemistry (IHC) for the Nos2 
protein was used to confirm its expression as seen in the qPCR array. (Figure 13B) 
Nos2 (stained in green) is highly expressed in LLC1 tumoroids. Many of the other 
stemness genes shown to increase in LLC1 cultured on scaffold were also increased in 
human cell lines cultured on scaffold for 6 days, albeit at a somewhat lower fold change. 
(Figure 13C) Taken together, this data demonstrates that the effects of the scaffold 
culture are not cell line specific and can promote stem-ness in human cancer cells as 
well as mouse cells. 
 
4.3 Discussion 
We are not the first to demonstrate an increase in CSC markers through culture on a 
fibrous scaffold, as Feng et. al. have also reported this phenomenon reporting increased 
expression of CSC markers Oct3/4, Sox2, and ALDH in breast cancer cell lines cultured 
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on a polycaprolactone scaffold. However, we have significantly advanced the field by 
performing an extensive characterization of the phenomenon as well as validating the 
CSC expansion observed on our novel scaffold material using multiple in vitro methods 
as well as in vivo tumor initiation [89]. We have demonstrated that our tumoroid platform 
can be used with both mouse and human cells with varying genetic background and 
that it is able to expand the expression of relevant CSC markers to each cell line (ALDH 
in LLC1 and CD44+/24- in A549). In addition to our own validations, other groups have 
studied the relevance of ALDH in LLC1 cells and CD44 in A549 cells which adds 
support to the claim that tumoroids grown on our scaffold are truly enriched in CSCs 
[40, 90-92].  
We have successfully utilized the tumoroid platform to generate and maintain 
large numbers of CSCs separate from their bulk tumor cells enabling full scale 
experiments such as RNA and protein isolation from CSCs, in vivo tumor initiation, and 
drug screening. Through the study of gene expression changes occurring as CSCs are 
maintained within tumoroids, we have identified the Wnt/β-catenin pathway as a major 
driver not only in mouse LLC1 cells but also in multiple human NSCLC cell lines. This 
phenomenon will be explored in greater detail in the coming chapters.  
Nevertheless, some aspects of CSC expansion in the tumoroid model remain to 
be explored. The full significance of the NO production increase we observed in 
tumoroids remains unclear. Because Nos2 is a Wnt target gene it provides some 
evidence that β- catenin activity is increased by scaffold culture. iNOS is known to 
promote drug resistance in lung cancer by activation of the canonical Wnt pathway 
through inhibition of DKK1 and to promote the growth of CSC in glioma via the Notch 
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pathway [93]16, 17). In this way, iNOS may be acting in a positive feedback loop to 
promote stemness in tumoroid cultures. The NO which is released by these CSCs may 
also play a role in increasing vascular permeability and inducing immune cell anergy, 
but this area requires further investigation.  
The significance of the difference in expression patterns of individual CSC target genes 
seen in figures 13-14 may provide some insight into how CSCs arise in the presence of 
differing driver mutations. For example, even though Wnt/β-catenin is implicated in the 
process of CSC proliferation, different Wnt genes were observed to be active in each 
cell line with some such as the common Wnt responsive gene c-myc not observed to 
increase at all [94, 95]. This is most likely due to the context specificity of the Wnt 
pathway and its many segments (both canonical and non-canonical) that will be 
discussed in detail in chapter 7. Despite the status of c-myc as a reporter of canonical 
Wnt activation, alternative Wnt activation can actually cause a decrease in c-myc 
expression especially in the context of increased CD44 [96, 97]. Despite the present 
validation of the tumoroid model of CSC proliferation, the details of the molecular 
mechanism behind the increased CSC proliferation remain unclear. Due to the facts that 
the 3D scaffold provides greater surface area for cells to attach and cells cultured on the 
scaffold come together to form 3D tumor-spheres increasing their cell-cell interaction, it 
is logical that stimulation of cell adhesion molecules could be responsible for the 
expansion of CSCs that occurs in this model but more work must be done to determine 
the specific mechanisms involved.  
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CHAPTER 5 
 A Novel Mechanism Regulating CSC Expansion (Natriuretic Peptide Receptor A)  
 
5.1     Introduction  
 Natriuretic peptide receptor A (NPRA) is the cell surface receptor for atrial natriuretic 
peptide (ANP). NPRA is found in many tissues including kidney, brain, ovaries, and 
endothelium [98]. NPRA functions as a guanylyl cyclase converting GTP into cGMP 
Figure 14. The Functions of ANP/NPRA Signaling 
ANP is produced by the heart in response to stress/high blood pressure. It is 
recognized by NPRA in the kidney leading to both natriuresis (excretion of 
sodium) and vasodilation through the renin angiotensin pathway. Because NPRA 
is a receptor guanylate cyclase it can also activate PKG in other tissues including 
in embryonic stem cells where it maintains pluripotency through an Oct4/Nanog 
dependent mechanism. 
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upon its binding to ANP which in turn can activate multiple downstream signaling 
pathways.  ANP is a peptide hormone produced by the heart with diuretic and natriuretic 
properties [99]. This is the primary function of ANP/NPRA signaling; to decrease blood 
volume in response to cardiac stress as a mechanism to reduce blood pressure. 
However, ANP/NPRA signaling has also been shown to modulate inflammation and 
fibrosis in several animal models, as well as maintain self-renewal and pluripotency in 
embryonic stem cells [100-102]. (Figure 14) Natriuretic peptide receptors are found on 
immune cells including macrophages and dendritic cells, as well as MSCs [103]. NPRA 
specifically has been shown to reduce endothelial inflammation through its guanylyl 
cyclase activity [104]. Studies thus far indicate that the ANP-NPRA pathway plays a role 
in the healing process and may be an important contributor to the outcome of 
cardiovascular ischemia and myocardial infarction [105]. Studies from the Mohapatra 
lab have shown that a deficit in ANP-NPRA signaling reduces the SDF-1/CXCR4 
mediated homing of MSCs to tumors, indicating that a link between the NPRA and CSC 
associated CXCR4 pathways exists. However, the exact mechanism of this link and the 
specific cell types involved remains unclear [106].  
 Studies from our laboratory have shown that a blockade of ANP-NPRA signaling 
can reduce CXCR4 expression in tumor microenvironments, as well as reduce 
angiogenesis in aortic segments. Co-culture with MSCs can partially recover these 
effects [106]. Initially, angiogenic potential of aortas derived from WT and NPRA-KO 
mice were compared using an endothelial sprout assay. Results showed that NPRA-KO 
aortic sections exhibit reduced sprouting (angiogenesis), which was restored when co-
cultured with MSCs [106]. Reduced angiogenesis potential of NPRA-KO aortas co-
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related with decreased VEGF production in the culture [106]. This indicates that the 
presence of MSCs can promote angiogenesis and may aid in healing at sites of 
vascular damage. 
NPRA is overexpressed in many cancers but its role in tumor progression has 
not been extensively studied [107]. Because our previous studies suggest that NPRA is 
crucial for the growth of tumors these studies examining the specific role of NPRA in the 
tumor microenvironment with respect to drug resistance and CSC development will 
provide significant insight into how tumors progress to more aggressive forms and 
possibly identify novel targets to prevent this.  Natriuretic peptide receptors are found on 
many cell types including ECs, MDSCs, and are overexpressed in many cancers [108, 
109]. NPRA has been shown to play a role in tumor growth and angiogenesis [28]. 
However, the specific role of NPRA signaling in different cell types present in the tumor 
microenvironment is still unknown. Because CXCR4 and SDF-1 expression are reduced 
in NPRA KO tumors and recovered when NPRA WT mesenchymal stem cells are 
introduced it is likely that NPRA influences the migration and/or development of CAFs 
from MSC [106]. Previously published data from our group indicates that the NPRA 
pathway influences CXCR4 expression and is crucial to tumor formation in a knockout 
mouse model.  Both CXCR4 and its ligand CXCL-12 were greatly reduced in NPRA KO 
tumors.  
This data suggests that the NPRA signaling pathway is involved in tumor 
progression and may also be involved in CSC development. Therefore, the scaffold 
model will be used to study and further define the role that NPRA plays in the tumor-
stroma interaction. We hypothesize that NPRA expression will be increased during CSC 
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expansion and a reduction in NPRA signaling achieved by gene knockout or small 
molecule antagonists will reduce both CXCR4 expression and CSC development in 
cells cultured on scaffold. We further hypothesize that NPRA disruption will have a 
direct effect in reducing the metastatic, proliferative, and stem like properties of cancer 
cells. We are proposing to expand the CSC population in culture as described in 
chapter 4 and identify the molecular mechanisms responsible for this expansion. We 
aim to elucidate the role of NPRA signaling in the development of CSCs and regulation 
of the expression of the CSC marker CXCR4. This will represent a candidate signaling 
pathway influencing the development of CSCs.      
Upon completion of this aim, we will achieve a better understanding of the 
similarities and differences in CSC composition and behavior in different cell lines as 
well as tumor biopsies. We will gain new insight into the signals that influence CSC 
propagation, which may be useful in identification of drug targets. Furthermore, these 
studies will provide novel insight into the role of specific cells in the tumor 
microenvironment with respect to development of drug resistance and CSCs, as well as 
insight into how NPRA signaling in each cell type affects the tumor as a whole. Finally, 
we will have created and validated a novel culture environment that promotes the 
growth of CSCs to be used in future studies.  
The proposed work is innovative, because we aim to determine the factors and 
signals that contribute to CSC proliferation. This work is also innovative because it will 
reveal for the first time the influence of the NPRA pathway on CSC development and 
specifically identify stromal conditions important to this process. This work will allow 
CSC populations isolated by different methods to be cultured and studied more easily 
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leading to better characterizations and refinement of in vitro cancer models, as well as 
identification of NPRA related drug targets to limit CSC development in vivo.   
 
5.2      Results 
     After establishing that CSCs are enriched in LLC1 tumoroids in chapter 4, we next 
examined weather the increase we saw in CSC markers was accompanied by an 
increase in NPRA expression. LLC1 tumoroids were stained for ALDH activity and co-
stained with fluorophore conjugated antibodies for either NPRA or CXCR4. Samples 
were gated into ALDH high and ALDH low populations and back-gated to show the 
Figure 15.Increased ALDH Activity Coincides with Increased NPRA and 
CXCR4 Expression in Tumoroids 
A. NPRA and CXCR4 expression in LLC1 cultured as monolayer.  B. NPRA and 
ALDH co-expression in LLC1 tumoroids. C. CXCR4 and ALDH co-expression in 
LLC1 tumoroids. 
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distribution of NPRA or CXCR4 between them. LLC1 tumoroids with high ALDH activity 
were found to be 43% NPRA+. However, the NPRA+ cells (in purple) were fairly evenly 
distributed among the ALDH+ and the ALDH- cells. (Figure 15B) The same LLC1 
tumoroids were found to contain 6% CXCR4+ cells (in orange), the majority of which co-
stained for high ALDH activity (Figure 15C). Comparing between monolayer and 
tumoroids reveals that tumoroid culture caused a relatively small increase in NPRA cell 
surface expression in LLC1 but does cause a significant increase in CXCR4 expression. 
(Figure 15C) 
      A similar analysis was performed on H460 tumor spheres grown in low attachment 
conditions. Tumor sphere culture was observed to cause an increase in both NPRA 
Figure 16. Increased CD44+/24- Population Coincides with Increased NPRA 
and CXCR4 Expression in Tumoroids 
A. H460 cultured as monolayer and tumorspheres were assayed for NPRA 
expression and CD44+/24- population by flow cytometry. 
B. Expression of NPRA and CXCR4 genes were compared by qPCR in H460 
monolayer and tumoroids. N=3 *p≤0.05 
 
A 
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expression (from 6.4% to 40%) and the CD44+/24- population (16% to 26%). (Figure 
16A) mRNA expression was also checked in tumor spheres vs monolayer. Both NPRA 
and CXCR4 expression was significantly increased in the tumorspheres.  
NPRA was observed to increase in both the tumor sphere and tumoroid models, 
so NPRA levels were also analyzed in a model of lung cancer drug tolerance. H1975 
cells were exposed to the epidermal growth factor receptor (EGFR) inhibitor, Lapatinib, 
at sub lethal concentrations to observe how they respond to treatment at the early 
stages of developing drug resistance.  After 20 days of exposure to the drug it was 
determined that their IC50 for Lapatinib was increased H1975-drug tolerant (H1975-DT) 
cells. (Figure 17A) Moreover, qPCR study revealed that the H1975-DT cells had 
Figure 17. Drug Tolerance is Correlated with Increased NPRA Expression 
A. Increased IC50 was confirmed in lapatinib tolerant H1975 cells by CellTiterGlo 
assay. 
B. NPRA gene expression was assayed by qPCR in H1975 parental, and 
Lapatanib tolerant cells. N=3 *p≤0.05 
C. NPRA receptor expression was assayed by flow cytometry in H1975 parental 
and Lapatanib tolerant cells. 
 
53 
 
significantly increased expression of NPRA. (Figure 17B) This increase was confirmed 
by flow cytometry, where H1975-DT were observed to have a 17% increase in NPRA on 
their cell surface. (Figure 17C)   
NPRA expression was elevated in both models of CSCs and drug tolerance, so 
we wanted to test the effects of inhibiting NPRA signaling to determine whether the 
inhibition would have an effect on the expression of CSC markers. H1975 were cultured 
as tumoroids and their CXCR4 expression was assayed with or without treatment with 
the NPRA inhibitor, anantin. CXCR4 expression was observed to increase in H1975 
tumoroids compared to monolayer and decrease in tumoroids treated with anantin. 
(Figure 18A-B)  
Figure 18.  NPRA Inhibition Reduces CXCR4 and CD44+/24- Expression 
A. H1975 cells were cultured for 6 days as monolayer on scaffold, or on scaffold 
with 1μM anantin and CXCR4 receptor expression was assayed by flow 
cytometry. The graph (B) shows the percentage of CXCR4+ cells in each group. 
LLC1 cells cultured as monolayer or tumoroids and treated with 1μM anantin. The 
graph (C) shows the levels of CXCR4+ and CD44+/24- in LLC1 cells with or 
without anantin treatment. 
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This experiment was repeated using LLC1 cells and it was observed that 
CXCR4, CD44+/24-, (Figure 18C) and ALDH+ (Figure 19A) markers are decreased in 
LLC1 tumoroids treated with anantin. After finding that NPRA inhibition was able to 
decrease cell surface CXCR4 in multiple cell lines, the effects of NPRA inhibition on the 
CXCR4 promoter were investigated using a luciferase based promotor reporter 
construct to determine if NPRA signaling regulates CXCR4 transcription. When LLC1 
cells were stimulated with the inflammation inducing bacterial LPS their CXCR4 
Figure 19.  NPRA Inhibition Reduces ALDH Activity and Activity of the 
CXCR4 Promoter 
A. LLC1 cells were cultured as monolayer or on scaffold for 6 days. Cells on 
scaffold were treated with either 10uM anantin or vehicle after 3 days. On day 6 
ALDH activity was assayed by flow cytometry using ALDEFLuor. 
B. LLC1 cells were transfected with a CXCR4 promoter reporter plasmid. Two 
days after transfection cells were stimulated with 1μg/mL LPS and treated with 
either 1uM anantin or vehicle. Luciferase activity was assayed after 24hr of 
treatment. N=3 
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promotor was activated as expected, however when the cells were co-treated with 
anantin, CXCR4 promotor activity remained the same as untreated. (Figure 19B)  
     Due to several issues in the use of anantin to inhibit NPRA inherent to its cyclic 
polypeptide structure (high cost, short half-life, and high dose needed) alternate 
methods of NPRA inhibition were investigated to further study the effects of NPRA on 
CSC growth. Towards this end, a CRISPR Cas/9 gene knockout technique was used to 
create an NPRA knockout H1299 cell line. Following transfection with a commercially 
available all in one CRISPR plasmid targeting NPRA, individual cells were isolated to 
form clonally derived colonies. These colonies were tested for NPRA expression by flow 
Figure 20. Use of CRISPR/Cas9 to Create an NPRA Knockout Cell Line 
A. H1299 cells were transfected with an all in one CRISPR/Cas9 plasmid construct 
containing guide RNA sequences for the NPRA gene. Following transfection, cells 
were cultured as individual colonies and colonies were selected and assayed for 
NPRA expression by flow cytometry. NPRA expression for colony #1 is plotted as 
both dot plot (A) and histogram (B) parental H1299 and secondary antibody only 
are provided as positive and negative controls. 
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cytometry to determine if the knockout was successful. One colony showed a significant 
reduction in NPRA from 68% to 14% (Figure 20A-B), so studies were continued with 
this colony to determine if its CSC properties were also reduced by NPRA KO.  
A sphere assay was performed to test if NPRA KO has any effect on sphere 
efficiency and therefore self-renewal ability. Both parental H1299 and NPRA KO H1299 
were able to form spheres in a similar distribution of sizes. (Figure 21A) However, the 
NPRA wild type H1299 formed ~twice as many spheres as the NPRA KO. This 
reduction in sphere forming ability in the NPRA KO H1299 indicated reduced stemness.  
 
To validate this finding, the tumor initiation ability of NPRA KO H1299 was 
determined. NSG mice were injected subcutaneously with WT cells in the right flank and 
KO cells in the left flank and tumor growth was monitored by caliper measurement. Both 
WT and KO cells were compared in each mouse to control for individual variation 
between mice. Tumors from both WT and NPRA KO were observed to increase in size 
from day 30 post injection to day 50. However, in each mouse the NPRA KO tumor 
Figure 21. NPRA Knockout Reduced Sphere Formation Ability 
Sphere formation ability was assayed in NPRA-KO H1299 vs parental H1299 
cells. The size distribution of spheres and the sphere efficiency values for each 
group are depicted. Sphere efficiency = cells plated/ # of spheres observed. N=3   
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grew more slowly and remained smaller in size compared to the NPRA WT tumor. 
(Figure 22A)  
 
Due to the fact that we observed that NPRA KO in cancer cells did not prevent 
tumors from growing, we decided to investigate NPRA KO in the tumor stroma. To 
determine how NPRA KO in the non-cancerous cells of the tumor microenvironment 
would affect tumor growth we obtained commercially available NPRA KO mice of the 
C57 BL/6 background and used them to study the growth of LLC1 tumors in an 
environment lacking NPRA. Previous studies from our Lab have showed that LLC1 
monolayer cells are not able to efficiently form tumors in NPRA KO mice, so we used 
LLC1 cells derived from tumor sphere culture to compare subcutaneous tumor growth in 
Figure 22. NPRA Knockout in Tumor or Stroma Reduces Tumor Growth 
 A. NPRA KO H1299 cells were used to initiate tumors in NSG Mice and growth 
was monitored over 60 days (N=3).  Mice were numbered 1-3 and each mouse 
received 3x10
6 
WT cells in the right flank and 3x10
6
 NPRA-KO cells in the left 
flank. 
B. Subcutaneous flank tumors were grown in NPRA KO mice using LLC 
tumorspheres at the indicated cell numbers (x1,000) (N=2) *p≤0.05 
 
* 
* 
* 
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NPRA WT and NPRA KO mice. Monitoring tumors initiated with decreasing numbers of 
cells revealed that tumors were able to grow much faster and to larger size in the WT 
mice when initiated with either 100,000 or 20,000 cells. (Figure 22B) No difference was 
observed in tumors initiated with 10,000 cells in the 30 day time period of the 
experiment. This is likely due to the much slower growth kinetics in tumors initiated with 
such a low cell number. 
 
5.3      Discussion 
While NPRA has been previously demonstrated to play a role in embryonic stem 
cell pluripotency and the migration of mesenchymal stromal cells, to our knowledge we 
have presented herein the first indication of NPRA’s role in maintaining CSC or drug 
resistant populations of cancer cells. Other groups are beginning to investigate the role 
of NPRA in cancer including studies showing that NPRA can increase invasion and 
migration in squamous cell carcinoma and promote gastric cancer development 
supporting our findings that it may play an important role in the progression of lung 
cancer [110-112].   
We did not consistently see dramatic increases in NPRA expression as a result 
of tumoroid culture, and indeed have previously shown that NPRA is often 
overexpressed in cancer cell lines grown as monolayer, indicating that NPRA itself may 
not be a good marker for CSC identification [109]. Previously published work 
demonstrates that NPRA is overexpressed in many types of cancer including in the 
LLC1 cell line and in vivo tumors. Therefore, signaling through NPRA may be important 
in supporting survival and/or growth of these cancers. The results presented here 
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support this conclusion, as we have demonstrated that increases in NPRA expression 
are associated with increases in CSC markers (ALDH, CD44+/24-, and CXCR4) as well 
as functional properties of CSCs including drug resistance, self-renewal, and the ability 
for tumors to grow in vivo. Furthermore, we have demonstrated that by inhibiting NPRA 
signaling, either using anantin or NPRA KO, we were able to reduce the expression of 
both ALDH and CXCR4 in lung cancer cells and simultaneously reduce their self-
renewal and tumor initiation. 
While the role of NPRA in lung cancer CSCs requires further study, we have 
begun to reveal a possible regulatory mechanism by showing that inhibition of NPRA 
signaling can reduce the transcriptional activity of the CXCR4 promotor. This may lead 
to future therapeutic intervention as increased CXCR4 expression has been associated 
not only with CSC growth, but also metastasis of cancer cells and migration of stromal 
cells into tumors where they support tumor growth [41, 42, 106, 113]. 
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CHAPTER 6 
Actinomycin D and Telmisartan Combination Treatment Targets CSC and 
Reduces Tumor Burden 
 
6.1     Introduction  
     As described in chapter 1, a major goal of this project is to utilize the 3D tumoroid 
CSC model to identify novel therapies to target and destroy CSC. Since we have 
established in chapter 4 that 3D tumoroids are indeed enriched in CSC we 
subsequently began testing anti-cancer drugs to determine whether they could block 
this expansion. We started by using a primary drug screen of the NCI diversity set of 
compounds in an established (monolayer) model of drug resistant cancer (MCF-7 Dox 
cell line) in order to identify lead compounds [114]. Subsequently, a secondary screen 
was performed using the NSCLC cell line H460 and Actinomycin D (AD) was identified 
as the compound able to reduce cell viability most potently in both screens (Table 3). In 
addition, we went on to determine that AD was also able to reduce Sox-2 expression in 
breast cancer tumoroids thereby reducing stemness [115]. Therefore, since we have 
identified in chapter 4 that ALDH expression is a valid marker for CSC in the LLC1 cell 
line, we hypothesized that treating LLC1 tumoroids with AD would result in a reduction 
in ALDH activity. We further hypothesized that if AD is successful in targeting CSC it 
would be effective in reducing the viability of not only LLC1 tumoroids but also 
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tumoroids generated from human NSCLC cell lines and that this anti-CSC effect would 
translate to in vivo mouse models of NSCLC as well.    
     The anti-cancer activity of AD has been known since the 1950’s when it was one of 
the first antibiotics discovered to be effective in the treatment of tumors [116, 117]. Its 
structure is a cyclic peptide, and it is produced by actinomyces soil bacteria where it 
was first discovered in the 1940’s  [118]. Actinomycin D exhibits genotoxic anti-
proliferative and anti-cancer effects by binding to DNA at GpC sites where it inhibits 
RNA polymerases from accessing the DNA thereby inhibiting transcription [119, 120]. It 
has also been shown to inhibit DNA topoisomerase activity resulting in increased stress 
Table 3. Drug Screening with the NCI Diversity Set in the H460 Cell Line 
 Cell viability was assayed using CellTiter Glo and IC50 calculated using 
Graph pad prism software. 
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on the DNA molecule and ultimately double-stranded breaks [120]. Through these 
mechanisms, AD has been shown to induce apoptosis in many cancer cell lines [115, 
121-123]. Due to its potent activity, AD was approved by the FDA to treat Wilms tumor, 
rhabdomyosarcoma, and choriocarcinoma in 1964 under the trade name Cosmegen. 
Since its approval AD has been used as a chemotherapy in the clinic however its use 
and effectiveness have been limited by its dose-limiting side effects including 
immunosuppression, fatigue, ulcers, and diarrhea [124, 125]. 
     In addition to its use as a primary chemotherapy, in recent years AD has been 
shown to be effective in cyclotherapy. The principle of cyclotherapy states that because 
many cancer therapies target rapidly dividing cells side effects of these therapies could 
be minimized if non-cancerous cells could selectively be made to stop dividing during 
treatment [126]. Towards this end, AD has been given in low doses to activate the P-53 
DNA damage response in non-cancerous cells causing cell cycle arrest after which 
point they will not be harmed by high dose chemotherapies [123, 126, 127]. 
     Because AD has been shown to be an effective cancer therapy both in the literature 
and by our preliminary screen, but its use is limited by side effects we considered 
combining AD with other drugs in an effort to reduce the dose required while 
maintaining its anti-cancer and anti- CSC effects. To achieve this goal, we have chosen 
the drug Telmisartan (TS), an angiotensin II receptor antagonist developed by 
Boehringer Ingelheim as an anti-hypertensive agent. It was selected for combination 
therapy with AD due to its well-known effect reducing collagen production in the tumor 
microenvironment thereby increasing the permeability of tumors and increasing drug 
penetration into them [128, 129]. However, TS is also known to have other effects in 
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models of cancer that make it an attractive candidate for combination therapy.  It has 
been shown to inhibit the growth of the NSCLC cell line A549 as well as other cancers 
through inhibition of PI3k signaling.[130] It is also known to be an activator of 
peroxisome proliferator-activated receptor-γ(PPARγ) which can influence cellular 
metabolism and fatty acid oxidation [131, 132]. Finally, TS has also been used as a 
cardio protective agent to reduce the toxicity of anti-cancer therapies through an anti-
inflammatory mechanism dependent on ANG II inhibition [133]. For these reasons, we 
hypothesize that a therapy combining AD with TS (AD+TS) will act synergistically to 
reduce both the viability and the CSC properties of NSCLC in the tumoroid model as 
well as in vivo models. 
 
6.2      Results 
IC50 values were determined for AD in LLC1, A549 and H1299 cell lines cultured either 
as monolayer or tumoroids to ensure subsequent experiments were carried out using 
sub-lethal treatments. AD was found to be very toxic to these cells cultured as a 
monolayer with IC50 values of 0.63nM (LLC1), 1.28nM (H1299), and 1.64nM (A549) 
(Figure 23A). Tumoroid culture was found to slightly raise the IC50 values for all cell 
lines indicating that the tumoroid model better replicates the in vivo microenvironment 
where drug resistance is increased; with IC50 values of 90nM (LLC1), 40nM (H1299), 
and 5nM (A549) (Figure 23B). TS alone was found to be non-toxic at the relevant 
therapeutic concentrations of 1-10µM (Figure 23C) 
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Figure 23. AD Reduces Viability in both Monolayer and Tumoroid Cultures of 
Lung Cancer Cell Lines 
Dose response curves and IC50 values for mouse and human lung cancer cell 
lines cultured on monolayer(A) vs 3D scaffold(B). Cells were plated on scaffold in 
96 well plates at a density of 5,000 cells per well. Serial dilutions of AD were added 
on day 4 and cell viability was assayed on day 6 by CellTiter-Glo. N=3.  Cell 
viability was also assayed after 48hr treatment with varying concentrations of TS 
(C).  
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   To test whether AD treatment reduces stem-ness in addition to reducing cell viability, 
a sphere formation assay was performed. AD was found to be able to reduce the 
sphere forming efficiency of isolated ALDH high cells from 4.8% in untreated cells down 
to 2.2% with only a 0.5nM AD treatment (Figure 24A). This indicates that AD is reducing 
the stemness characteristics of these cells.  Because the CSC marker ALDH was found 
to be highly active in LLC1 cells cultured under low attachment conditions during the 
tumorsphere assay, we tested whether AD treatment would be able to reduce ALDH 
activity during tumorsphere growth. Indeed, treatment with as little as 3nM AD was able 
Figure 24. Actinomycin D Reduces Sphere Formation Ability and ALDH 
Activity in LLC1 Tumoroids 
A. Sphere formation efficiency of LLC1 sorted ALDH high cells with or without AD 
treatment (0.5nM) N=3*p≤0.05 
B-C. ALDH activity of LLC1 cells cultured as spheres on low attachment plates with 
or without 3nM AD treatment (B) or as tumoroids on 3D scaffold after treatment 
with escalating doses of AD (C), as assayed by flow cytometry using ALDEFluor kit.  
ALDH 
ALDH 
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to reduce ALDH activity in tumorspheres from 64% to 13% (Figure 24B). LLC1 cells 
cultured as tumoroids on scaffold were also treated with AD in increasing 
concentrations (3-48nM), and a dose-dependent reduction in ALDH activity was 
observed (Figure 24C). Therefore, AD may be able to reduce the stem like properties of 
cancer cells as evidenced by its ability to lower ALDH activity and sphere formation. 
 
 
     Additionally, TS was tested for its ability to synergize with AD to further reduce the 
viability of lung cancer cell lines treated with AD. LLC1 cultured on scaffold were treated 
with a combination of AD at varying concentrations plus 10µM TS. (Figure 25A) The 
addition of TS was found to reduce the IC50 of AD from 127nM to 52nM in a synergistic 
Figure 25. Actinomycin D Acts Synergistically with Telmisartan in Lung 
Cancer Tumoroids 
IC50 values were determined for cell lines cultured as tumoroids on scaffold 
LLC1(A) and, H460, H1299, A549 (B) treated with AD in the presence or absence 
of TS (10µM). Drugs were added on day 4 of culture and viability was assayed on 
day 6 using CellTiter Glo. Combination index was calculated using CompuSyn 
Software by comparing the effects of AD and TS alone vs in combination. IC50 and 
combination index values are provided in the associated table(C). 
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fashion. (Calculated using CompuSyn software)(Figure 25A-C) This suggests that 
through the addition of non-toxic concentrations of TS a low dose of AD may be 
sufficiently effective. This effect was also seen in tumoroid cultures of human lung 
cancer cell lines (Figure 25B-C) indicating that the effects of AD+TS treatment are not 
cell line specific.  
 
     Next, an analysis was performed using Ingenuity Pathway Analysis(IPA) software 
aiming to predict mechanisms of interaction between AD and TS based on published 
findings present in the IPA database. (Figure 26) This analysis predicted 11 factors to 
directly interact with both drugs including caspase3, reactive oxygen species (ROS), 
Figure 26.  Prediction of Mechanisms of Synergy Between AD and TS 
IPA was used to find molecules that are affected by both AD and TS. Direct 
interactions are highlighted in red, indirect interactions are shown in grey. CASP3, 
NOS2, and ROS were selected for further study. 
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and Nos2. We have already seen in chapter 4 how Nos2 is up-regulated in the tumoroid 
model so the fact that AD+TS are known to target it was encouraging.  
 
     The 3D tumoroid morphology previously described as a key feature of scaffold 
culture was assayed following drug treatment to determine if the treatments had any 
effect on the overall morphology of the cultures in addition to their ability to block the 
cells from acquiring stem-like properties. The combination treatment of AD plus TS was 
found to change the morphology of LLC1 cultured on scaffold. (Figure 27A) When cells 
were treated with TS or AD alone, they retained the same 3D tumoroid structure as 
untreated cells. However, when LLC1 were treated with AD+TS, the tumoroids were 
seen to break up, and more isolated single cells were visible.  This change is indicative 
of the increased potency of the combination treatment since AD alone seems able to 
reduce stemness as assayed by ALDH activity; however, it is not able to break up the 
tumoroid structures at this low concentration without the addition of TS. Following 
observations of morphology, tumoroids from these treatment groups were assayed for 
ALDH activity. AD was found to greatly reduce ALDH activity which is consistent with 
previous experiments, however, AD+TS was able to reduce ALDH activity further, to 0% 
(Figure 27B). To investigate the mechanism of cell death occurring as a result of AD+TS 
treatment, a western immunoassay was performed to assay levels of PARP and 
caspase3, two proteins critical to promoting apoptosis.(Figure 27C) Following AD+TS 
treatment levels of both cleaved PARP and cleaved caspase3 were found to increase 
indicating that LLC1 tumoroids were undergoing apoptosis. 
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      In addition to the ability of AD to reduce ALDH activity and sphere formation 
efficiency the effect of AD on several of the CSC related genes identified by the qPCR 
array were assayed. Scaffold cultured LLC treated with AD and AD+TS were found to 
have reduced expression of several stemness-related genes previously shown to have 
increased as a result of scaffold culture such as abcg2, dvl3, nos2, and plat. (Figure 28) 
The combination treatment reduced expression of all genes assayed with the exception 
of Oct4. TS alone was shown to reduce expression of CD44, Oct4, and Nanog revealing 
ALDH 
Figure 27. Combination of AD and TS Further Reduces ALDH Activity and 
Causes Tumoroids to Undergo Apoptosis 
A. LLC1 cells were cultured as tumoroids on scaffold. On day 4 wells were treated 
with either AD, TS, or both in combination. On day 6 cells on scaffold were stained 
with Nuc Blue dye and examined by fluorescent microscopy. 
B. LLC1 cells cultured and treated as in (A) were collected on day 6 of culture and 
ALDH activity was assayed by flow cytometry using ALDEFluor kit. 
C. LLC1 cells were cultured and treated as in (A). On day 6 tumoroids were 
removed from scaffold, total protein was isolated, and expression of PARP and 
Caspase3 (both full length and cleaved) were assayed using the Wes system.  
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that it may have broader anti-CSC effects than merely increasing the penetration of AD 
into tumors. 
     To assay of the effectiveness of AD and AD+TS treatments in reducing tumor burden 
and CSC growth, these treatments were tested in multiple mouse models of lung 
cancer. Cells cultured in monolayer as well as CSC enriched scaffold cultures were 
tested to compare the effectiveness of these treatments on CSC specifically. One 
million LLC1   monolayer cells were injected subcutaneously into the flanks of C57BL/6 
mice to initiate tumors. Starting on day 10-post injection, intratumoral treatments of AD 
(25µg/kg or 50µg/kg) were administered every 3 days for a total of 3 treatments. Tumor 
diameters were measured via caliper on days 11, 14, and 17. Only the 50µg/kg 
Figure 28. Combination of Actinomycin D and Telmisartan Reduces 
Expression of CSC Genes in Tumoroids 
LLC1 cells were cultured as tumoroids and treated as in Figure 25. Cells were 
collected on day 6, RNA was isolated by affinity column method, and expression of 
CSC related genes were assayed by qPCR. Results were compared to LLC1 
monolayer culture as control. N=3 *p≤0.05  
 
* * * 
* * 
* 
* * 
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treatment was found to significantly reduce tumor size, so this dose of AD was chosen 
for subsequent experiments.  To determine the anti-tumor effect of TS this experiment 
was repeated with the addition of TS and AD+TS groups using only 50 µg/kg AD and 1 
mg/kg TS. Both AD and the combination treatment reduced tumor size although the 
combination had a more significant effect while TS treatment did not reduce tumor size. 
(Figure 29A) We also tested the effectiveness of AD+TS treatment in a xenograft model 
using A549 subcutaneous flank tumors in Nod/SCIID mice. In this model we also found 
that TS treatment has no significant effect on tumor growth, AD was able to slow tumor 
growth, but AD+TS resulted in the greatest reduction in tumor size. (Figure 29B) 
 
     In a second experiment, 100,000 3rd generation scaffold cultured LLC1 were 
injected subcutaneously into the flanks of C57BL/6 mice. These tumors were treated 
intratumorally with a vehicle, AD (50µg/kg), or AD plus TS (1mg/kg) every 3 days 
beginning on day 10. Using 3rd generation scaffold cells to initiate tumors provides a 
greater number of initial CSC meaning fewer cells are required for the tumor to grow 
compared to cells derived from monolayer culture. In these 3rd generation tumors, we 
observed a stronger effect of the AD+TS treatment as evidenced by the larger 
difference in size between AD+TS tumors and tumors in the other treatment groups. 
(Figure 29C).  
     To assess the stemness of the tumor cells following treatment, the tumors from the 
LLC1 scaffold group were collected; one tumor from each group was digested to form 
single cell suspension, and was assayed for ALDH activity by flow cytometry. The TS, 
AD, and combination tumors were all found to have reduced ALDH activity compared to 
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the control group. (Figure 29D) This indicates that AD and AD+TS treatments are 
effective at reducing CSC in addition to reducing overall tumor size and burden. 
 
 
6.3      Discussion 
 Our results thus far have demonstrated a novel combination treatment (AD+TS) 
that is not only able to reduce the expression of stemness markers in lung cancer cells 
in vitro but also is able to reduce tumor growth in vivo. Using a novel 3D tumoroid model 
Figure 29. Combination of Actinomycin D and Telmisartan Reduces Tumor 
Growth and Stem-ness In Vivo 
A-C. In vivo tumor treatment. Cells were injected subcutaneously into the flanks of 
mice, 1 million LLC1 monolayer cells into C57/Bl6  (A) 5 million A549 monolayer 
cells into Nod/SCIID mice (B) or 100,000 LLC1 scaffold cells into C57/Bl6 (C). Mice 
were treated with 50µg/kg AD, 1mg/kg TS, or combination by intratumoral injection 
every 3 days starting when tumors reached 3mm in diameter. Tumor growth was 
monitored by caliper measurement and mice were sacrificed when tumors reached 
10mm in diameter. For all experiments N=3 control, 4 AD, 4 TS, 7 combination. D. 
Tumors initiated with LLC1 3rd generation scaffold cells were assayed for ALDH 
activity using ALDEFluor kit following treatment described in (B). *p≤0.05 
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to enrich and maintain CSC in lung cancer cell lines has allowed us to study the gene 
expression changes that occur as CSC grow. We have thus identified the Wnt pathway 
as crucial for lung CSC development and re-confirmed the importance of known targets 
such as Sox2, ALDH, and Nos2. Using published literature to predict possible 
interactions between AD and TS we have identified and validated the apoptosis-
inducing effects of AD+TS in lung cancer through a mechanism involving caspase-3 
cleavage. Through this synergistic action, AD and TS are able to significantly reduce the 
viability of cancer cells both in monolayer and tumoroid culture while simultaneously 
reducing expression of CSC marker genes, ALDH activity, and interfering with the ability 
of cells to form 3D tumoroids. This synergistic action was validated in vivo where 
AD+TS was found to significantly reduce both tumor growth and stemness via reduction 
in ALDH activity. 
While the mechanisms of AD’s anti-cancer activity are well known as stated in 
the introduction to this chapter, the use of TS in cancer therapy and specifically its 
combination warrant further study, some of which will be revealed in the following 
chapter. Because TS is a partial agonist of PPARγ, which causes metabolic changes 
within tumors to increase fatty acid oxidation possibly counteracting the Warburg effect 
it may play a secondary role disrupting the metabolism of CSC [131-133]. The use of 
metabolism to target CSC is a rapidly expanding area of research and TS’s role in this 
area warrants further investigation [59, 134, 135]. It has also been used to help reduce 
the toxicity of co-administered chemotherapeutics as its Ang-II inhibition has an anti-
inflammatory effect that is cardio-protective indicating that the use of TS can have 
additional benefits outside the targeting of CSC [133]. 
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CHAPTER 7 
AD and TS Combination Treatment Reduces Stemness in Lung Cancer CSC 
through Modulation of the Wnt/β-catenin Signaling Pathway  
 
7.1 Introduction  
As described in chapter 4, the expansion of lung CSC observed in 3D tumoroid culture 
is associated with increased expression of several Wnt/β-catenin target genes (Sox2, 
ALDH, CXCR4, and Nos2). Therefore, in addition to the anti-ALDH and pro-apoptotic 
effects described in chapter 6 we hypothesized that combined treatment of AD and TS 
might be mediating its effects through alterations to the pro-CSC Wnt/β-catenin 
pathway. 
Wnt/β-catenin is a core stemness pathway which along with Notch, sonic hedgehog, 
and Janus-activated kinase/signal transducer and activator of transcription (JAK-STAT), 
is known to regulate self-renewal and proliferation both in embryonic stem cells as well 
as CSC [24, 60, 136-138]. Its role in driving the growth and expansion of CSC has been 
extensively studied, and as mentioned in chapter 2, it is one of the pathways currently 
under investigation for novel inhibitors to block CSC expansion. 
     Wnt signaling involves a vast interconnected network of proteins that has classically 
been divided into canonical and non-canonical pathways. As research has progressed, 
increasing complexity has been revealed within the non-canonical pathways and they 
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can now be further broken down into three sub-categories; the planar cell polarity 
pathway, the Wnt/calcium pathway, and the non-canonical Wnt5/Fzd2 pathway [139]. 
(See Figure 30 for comparisons of canonical and non-canonical Wnt signaling 
pathways). Taken together these pathways are known to regulate expression of over 
125 target genes [140, 141]. In general, Wnt signaling is initiated when one of the 19 
known Wnt ligands binds to one of the ten isoforms of the frizzled receptor (FZD) in 
complex with the co-receptor LDL-related protein receptor 5/6 (LRP-5/6)  on the cell 
surface [142]. This leads to the phosphorylation of LRP6 by GS3K/ CK1γ and 
recruitment of disheveled (Dvl) which breaks up the β-catenin destruction complex 
Figure 30. Mechanisms of Canonical vs Non-Canonical Wnt Signaling 
Diagram depicting the different mechanisms and outcomes of canonical 
Wnt/β-catenin vs non-canonical Wnt/β-catenin signaling. 
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(composed of GSK3β, APC, Axin, and Ck1α). This typically keeps cytoplasmic β-
catenin levels low by tagging it for proteasomal degradation. Therefore, when the 
activity of the destruction complex is inhibited, β-catenin is allowed to accumulate in the 
cytoplasm where it is stabilized and signaled to the nucleus by modifications such as 
phosphorylation and acetylation. In the nucleus, β-catenin complexes with TCF/LEF 
transcription factors to activate expression of their target genes. 
     Activation of non-canonical Wnt pathways can trigger distinct signaling events 
depending on the specific Wnt ligand involved and the members of the receptor 
complex that it binds to. For example, Wnt5 can bind to FZD in the absence of LRP5/6 
resulting in activation of either PKC/NFAT (protein kinase C/ nuclear factor of activated 
T-cell) or STAT3 target genes ultimately regulating cell adhesion and EMT.[142] Wnt5 
can also bind to receptor tyrosine kinase-like orphan receptor 2(ROR2) in the absence 
of FZD resulting in the destruction of β-catenin and inhibition of canonical Wnt signaling 
[143, 144].  
     We hypothesize that because the increase in stemness promoted by our tumoroid 
model is associated with increased β-catenin activity, that the ability of AD+TS to block 
stem-ness in this model may involve inhibition of the Wnt/β-catenin pathway. We further 
hypothesize that because these drugs are not known to be direct inhibitors of any Wnt 
signaling proteins, that their effects on the Wnt pathway may involve the production of 
ROS and/or activation of PPARγ since these are known effects of the drugs. 
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 7.2      Results 
In order to get a better understanding of the broader effects of AD+TS treatment, we 
have performed RNA sequencing (RNA-Seq) on the drug-treated LLC tumor samples. 
Sequencing was performed, by our collaborators at the Beth Israel Deaconess Medical 
Center genomics core. 403 total genes were found to have either significantly increased 
or decreased expression in the AD+TS group compared to control. (Figure 31A) 
However, only 13 genes were found to be differentially expressed in all treatment 
groups exhibiting the same trend after AD, TS, and AD+TS treatment. (Figure 31B)  
     The two genes found to increase in expression were Dmd and Abcb1. While Dmd is 
the largest gene (containing 2.2Mb) indicating a possibility that its identification is an 
artifact of sequence alignment it could be involved in stem cell depletion as it promotes 
asymmetric division in muscle stem cells leading to differentiation [145]. Abcb11 
encodes a bile salt transporter, which has also been known to transport drugs, so it may 
be upregulated as a survival response caused by drug treatment [146]. Among the 
decreased genes Lair1, Batf2, Gbp2, and Cxcl9 may have roles in stem-ness in this 
model. Lair1 is a cell signaling receptor typically found on hematopoietic cells however it 
is known to “exhaust tumor-initiating cells by apoptosis” in acute myeloid leukemia 
[147]. Batf2 promotes the formation of the β-catenin destruction complex resulting in 
GSK3β activation and β-catenin destruction [148]. Its expression may be decreased 
after treatment in an attempt to increase canonical Wnt signaling to support cell survival 
and proliferation. Gbp2 increases association between Dvl and GSK3β inhibiting 
GSK3β, therefore, a decrease in Gbp2 would reduce β-catenin activity by promoting its 
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phosphorylation by GSK3β [149].  This opposes the action of the Batf2 expression 
change indicating that the Wnt pathway may be dysregulated by our treatments. Cxcl9 
is a chemokine that functions to attract T cells which is typically produced following 
interferon-gamma stimulation. It is also known to increase activation of β-catenin in B 
cell lymphoma [150].  
     Ingenuity Pathway Analysis (IPA) was performed using this data to identify 
downstream effects of the observed expression changes. We found the expression 
changes caused by AD+TS treatment to be consistent with decreased incidence of 
tumors, decreased migration of cells, and changes in glucose metabolism. (Figure 32A) 
This indicates that TS treatment may be affecting glucose metabolism in LLC tumors, 
Figure 31. RNA-Seq Reveals Gene Expression Changes that Result from AD 
and TS Combination Treatment In Vivo 
 
A. Gene Expression Changes in Treated LLC1 Tumors. RNA was isolated from 
drug treated LLC1 tumors (Figure 29C) and RNAseq was performed to identify 
differentially expressed genes within the 4 treatment groups. The number of 
genes identified as either increased or decreased in expression unique to each 
treatment or common to multiple treatments are shown. 
B. Table depicting genes either increased or decreased in all (AD, TS, and 
AD+TS) treatment groups depicted in A. 
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and is consistent with its well-known PPARγ agonism. IPA analysis was also used to 
predict which cell signaling networks are likely to be inhibited by AD+TS treatment using 
the RNA-Seq data. Figure 32B shows two of the top predictions based on differentially 
expressed genes in AD+TS tumors vs control. These networks predicted to be inhibited 
by AD+TS treatment rely on STAT1 and STAT3 signaling, a pathway known to interact 
cooperatively with Wnt/β-catenin [151-153].  
Figure 32. AD and TS Combination Treatment Reduces Tumor Growth, 
Migration, and STAT1/3 Signaling In Vivo 
 IPA was used to predict the downstream effects of the genes found to be 
differentially expressed in the combination treatment vs control by RNA-Seq. A. 
depicts predicted downstream effects inhibiting tumor incidence, cell migration, 
and glucose metabolism. B. depicts predicted downregulation of networks in the 
STAT1/STAT3 pathway.  
 
80 
 
Since several differentially expressed genes identified by qPCR are involved in or 
targets of β-catenin signaling (Dvl2, Dvl3, STAT3, CD44, Oct4, Sox2) a TOPFLASH 
assay for activated β-catenin was performed to determine if β-catenin activity is being 
increased by scaffold culture and also if AD+ TS treatment is able to reduce β-catenin 
Figure 33. β-catenin Activity is Increased in Tumoroid Cultures and Reduced 
by AD and TS Combination Treatment  
A. LLC1 cells were cultured as monolayer or on scaffold. On day 2 of culture cells 
were transfected with a β-catenin reporter plasmid and luminescence was assayed 
at the indicated timepoints (D3-7). LLC1 monolayer were also transfected with β-
catenin reporter plasmid and treated with TS (1µM), AD(2.5nM) or combination 
after 24hr. Luminescence was assayed at 72hr. N=3 *p≤0.05. B. Relative β-catenin 
abundance and phosphorylation in drug treated LLC1 tumors was assayed using a 
Phospho antibody array (Full Moon Biosystems). Relative normalized fold change 
was calculated using Graph Pad Prism software. One way ANOVA was used to 
determine significance. N=6 *p≤0.05 
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activation. LLC1 cultured on scaffold were shown to have higher levels of active β-
catenin than LLC1 monolayer cultures (Figure 33A). Also, monolayer LLC1 cultures 
treated with AD + TS had significantly reduced levels of active β-catenin (Figure 33A-B). 
This finding is significant because β-catenin activity is known to drive both metastasis 
and the CSC phenotype in breast cancer, colon cancer, and hepatocellular carcinoma 
and because there are currently no drugs approved to target the Wnt/β-catenin 
pathway.(25-29) In addition, AD+TS treated tumors were found to express lower levels 
of both total and active phospho-β-catenin (Figure 33B). 
     To further investigate the effects of the combination treatment on the Wnt/β-catenin 
pathway we performed an analysis of protein phosphorylation on drug-treated LLC1 
tumor samples using an antibody array chip (Full Moon Biosystems). Overall activation 
of the Wnt pathway was reduced by the combination treatment and several key 
changes to the pathway were observed including decreased production of Wnt 5a and 
decreased activation of CaMk2 and CKI gamma indicating that the treatment may be 
affecting the Wnt/calcium pathway in addition to the canonical Wnt/β catenin pathway 
(Figure 34). Downstream effectors of the Wnt pathway were also found to be reduced 
following AD+TS treatment including phospho-MAPK, phospho-Src, and phospho-AKT 
indicating that the processes of cell growth and proliferation controlled by these 
pathways may be reduced by AD+TS treatment. This finding corroborates the RNA-Seq 
results shown in figure 32, which indicated decreased cell proliferation in LLC1 tumors 
following AD+TS treatment. 
    To confirm that the canonical Wnt pathway is inhibited by AD+TS treatment we 
performed western immunoassays for the Wnt ligand binding co-receptor LRP6. 
82 
 
Tumoroid culture was found to increase both the expression and phosphorylation of 
LRP6 compared to monolayer culture in LLC1, and AD+TS treatment was found to 
inhibit LRP6 expression. (Figure 35A-B).  This was repeated in protein isolated from 
drug-treated LLC1 tumors to confirm the phenomenon in vivo, and indeed total LRP6 
was found to be lower in the AD+TS group (Figure 35C). Phospho-LRP6 was not 
observed in tumor samples possibly due to a limitation of the antibody or lower 
abundance of the phosphor-protein in vivo. 
 
Figure 34. Activation of Canonical Wnt Signaling is Reduced by AD and TS 
Combination Treatment  
Relative protein abundance and phosphorylation for Wnt pathway proteins in drug 
treated LLC1 tumors. Protein was collected from drug treated LLC1 tumors and a 
phospho antibody array assay was performed to determine changes occurring in 
the Wnt pathway. (Full Moon Biosystems) Relative normalized fold change was 
calculated and graphed for select proteins using Graph Pad Prism software. N=6    
(*= decrease vs control) p≤0.05 
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Figure 35. Expression and Activation of the Wnt Co-Receptor LRP6 is 
Reduced by AD and TS Combination Treatment  
Expression of the frizzled co-receptor protein LRP6 was determined by western 
immunoassay in LLC cell line (A) and tumor (C) samples. In the LLC cell line 
levels of active phospo-LRP6 was also determined (B) and tumoroid groups were 
compared to monolayer as a control. Cells were treated with 10µM TS, 48nM AD 
or the combination for 48hr.  Assays were performed using the Wes system 
(Protein Simple).  
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     The IPA analysis also predicted AD and TS to interact via generation of reactive 
oxygen species. (ROS) Therefore we used a ROS indicator dye (CM-H2DCFDA) to 
determine whether ROS production is increased in LLC1 following treatment. Figure 36 
shows that TS is a potent activator of ROS resulting in a 19% increase after 1µM 
treatment. When combined with a low dose of AD (0.4nM), which is only able to 
generate a 5% increase on its own, the AD+TS combination worked synergistically to 
cause an almost  30% increase in ROS. 
Figure 36. AD and TS Combination Synergistically Increases Production of 
ROS 
Production of ROS was assayed in LLC1 monolayer cultures treated with 0.4nM 
AD, 1µM TS, or the combination for 48hr. The dye CM-H2DCFDA was used as an 
indicator of general oxidative stress. Staining was assessed using fluorescent 
microscopy (B) while brightfield images were also collected for each field as a 
reference (A). Staining was also assayed by flow cytometry using the FITC 
channel (C).  
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7.3     Discussion 
A significant in vivo mechanistic finding of our studies is that the efficacy of the 
novel AD+TS combination treatment approach involves anti-CSC effects, which are at 
least partially mediated by alterations in the Wnt/β-catenin pathway, leading to 
decreased activity of key cell proliferation signals and ultimately apoptosis through a 
mechanism involving increased ROS production and caspase-3 cleavage. This finding 
is significant in part because as discussed in chapter 4, expansion of CSC in the lung 
tumoroid model coincided with increased β-catenin transcriptional activity and 
expression of Wnt/β-catenin target genes highlighting the importance of this pathway 
driving the acquisition of the CSC phenotype. Indeed the enhanced cell-cell and cell-
scaffold interactions promoted by tumoroid growth may be crucial to initiating this β-
catenin activation either by signaling through the cell adhesion molecules E-cadherin or 
N-cadherin or through the rearrangement of adherens junctions, but more work is 
needed to determine the validity of this hypothesis.    
 By combining the techniques of RNA-Seq and phosphor-protein analysis, we 
have profiled the effects of AD+TS treatment on the Wnt/β-catenin pathway as well as 
its downstream effects on cellular properties such as migration, proliferation, and tumor 
growth. Wnt5a, which we have found to be elevated in LLC1 tumors and which was 
reduced by our combination treatment, has been reported to act as either a tumor 
promoter or tumor suppressor depending on the cancer type [154]. In NSCLC it has 
previously been associated with tumor cell proliferation and expansion of CSC [155, 
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156]. This diverse activity may be attributed to the fact that Wnt5a can either activate or 
inhibit β-catenin phosphorylation through the canonical Wnt pathway depending on the 
cellular context. Its function depends on its binding to ROR1/2 (receptor tyrosine kinase-
like orphan receptor) in the presence or absence of frizzled [157]. When Wnt5a 
activates β-catenin after binding to the FZD-4/5 LRP5/6 complex, downstream PPARγ 
activation is suppressed, and β-catenin/TCF target genes are transcribed [155, 158]. 
Wnt5a can also suppress PPARγ activation through the alternative Wnt/calcium 
pathway through a calmodulin-dependent mechanism involving NLK [158]. In this way, 
activation of canonical Wnt or Wnt/calcium signaling which lead to cell proliferation and 
acquisition of CSC traits can be linked to a decrease in PPARγ activity [159]. 
     Alternatively, when Wnt5a binds to ROR2 in the absence of FZD, β-catenin 
activation is inhibited. TS is known to activate PPARγ as a partial agonist, which can, in 
turn, inhibit activation of β-catenin either by stabilizing the APC/GS3kβ destruction 
complex or by inhibiting the translocation of β-catenin to the nucleus [160-163]. This 
mechanism has been shown to be involved in the differentiation of MSCs into 
osteoblasts [158]. The inhibition of β-catenin activation in this manner not only reduces 
its pro-proliferation signal but also reduces the cell’s ability to repair the DNA damage 
caused by AD treatment [164]. It is known that inhibition of the Wnt/β-catenin pathway 
can promote DNA damage in the presence of the genotoxic chemical benzo[a]pyrene, 
so it is likely to also promote DNA damage in the presence of genotoxic concentrations 
of AD [165]. In addition to inhibiting transcription, AD can also cause double-stranded 
breaks in DNA leading to increased levels of ROS, which in turn can enhance apoptosis 
[166-168]. This may further contribute to the apoptosis-inducing synergistic action of TS 
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in the combination treatment since other PPARγ agonists have been demonstrated to 
increase ROS levels in lung cancer cells by altering glucose metabolism to reduce 
glutathione levels ultimately resulting in cell cycle arrest [169]. This effect appears to be 
dependent on TS’s activation of PPARγ and therefore distinct from its angiotensin 
inhibition dependent anti-inflammatory, cyto-protective role. 
     The dual stimulation of ROS production that occurs as a result of the 
combination treatment may play a key role in the treatment’s ability to precisely target 
CSC through the Wnt pathway, since ROS themselves can regulate the transcriptional 
activity of β-catenin [170]. Our data show that the combination of genotoxic AD with 
TS’s multiple effects regulating metabolism and inflammation is able to reduce tumor 
burden and simultaneously reduce expression of CSC markers in both in vitro and in 
vivo models of lung cancer. TS is known to induce ROS production via activation of 
PPAR gamma, and TS is also known to inhibit JAK/STAT signaling[171]. TS alone has 
been reported to induce apoptosis in some cancer cell lines including prostate and 
colon, but conflicting reports suggest that this effect is not universal to all cancers. [172, 
173]. We have implicated Wnt signaling as a target of this treatment and reported the 
treatment’s effects on both the canonical and Wnt/calcium pathways. Future directions 
will include further investigation into the regulatory mechanism by which changes in 
ROS and PPARγ activity induced by these drugs are able to alter the transcription and 
function of Wnt target genes to reduce the stemness of CSC. 
In sum, our results thus far have demonstrated that CSCs expand in lung cancer 
tumoroids and tumors wherein the Wnt signaling pathway plays a crucial role in lung 
CSC development, and this signaling involves several important known targets such as 
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Sox2, ALDH, and Nos2. Further, novel combination treatment was designed using two 
known FDA-approved drugs, AD and TS, which not only reduced the expression of 
stemness markers in lung cancer tumoroids in vitro but also was able to reduce tumor 
growth in vivo. Moreover, the pivotal role of the Wnt signaling pathway was 
demonstrated in the synergism underlying the combination therapy.   
  
89 
 
 
 
 
CHAPTER 8 
Conclusion 
     In conclusion, we have demonstrated and validated a novel in vitro model for lung 
CSC culture and successfully used this model to identify both a novel pathway 
regulating CSC growth (NPRA) and a novel treatment targeting CSC (AD+TS). To our 
knowledge, our lab is the first to demonstrate the importance of NPRA signaling in CSC 
development linking it with increased self-renewal and tumor initiation. We are also the 
first to demonstrate the effectiveness of the AD+TS treatment both in vitro and in vivo 
targeting CSC and reducing tumor burden through a Wnt/ β-catenin dependent 
mechanism. 
     In chapter 4 we provided evidence that our 3D tumoroid model truly enhances the 
growth of CSC in lung cancer cell lines and biopsies finding a positive correlation 
between tumoroid growth and expression of the CSC markers including ALDH, 
CD44+/24-, and the transcription factors Sox2, Oct4, and Nanog. Also, we established 
that CSC within tumoroids identified by these markers were able to initiate tumors in 
vivo at low cell concentrations validating their status as true CSC. Through examination 
of the gene expression changes that occur in the tumoroid model, we identified Wnt/ β-
catenin signaling as a crucial pathway promoting lung CSC growth. This pathway has 
been previously described as a promotor of CSC in multiple cancers including lung, 
colon, and hepatocellular carcinoma lending support to the validity of the tumoroid 
model. 
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     In chapter 5 we have shown how the tumoroid model can be used to  enrich CSC in 
culture in an effort to discover novel pathways regulating their growth. We have 
identified that the expression of NPRA is correlated with CSC marker expression and 
that inhibition of NPRA signaling impairs the ability of lung CSC to self-renew and to 
initiate tumors. To our knowledge, this represents the first implication of the NPRA 
pathway as a driver of stem-ness in cancer revealing NPRA as a novel target for future 
studies aiming to develop treatments targeting CSC.  
Figure 37. Summary of changes to the Wnt pathway as a result of AD+TS 
Treatment 
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    In chapter 6 we demonstrate the effectiveness of the tumoroid model though 
validating by screening for CSC targeted drugs. We show that cells grown as tumoroids 
are more resistant to drug treatments and thus are a better replication of in vivo tumors. 
We have characterized the effects of our novel combination treatment (AD+TS) and its 
ability to decrease lung cancer tumoroid viability, ALDH activity, self-renewal through 
sphere formation, and even formation of the tumoroids themselves resulting in the 
induction of apoptosis through cleavage of caspase-3.  The anti-CSC action of the 
AD+TS combination treatment was further validated using both an in vivo syngenic 
model and an in vivo xenograft model where it decreased tumor size and growth rate in 
addition to ALDH activity. 
     Finally, in chapter 7 we investigated the molecular mechanisms responsible for 
AD+TS’s ability to target CSC and the involvement of Wnt/ β-catenin signaling. We 
began by surveying the gene expression changes caused by AD+TS treatment in vivo 
using RNASeq which confirmed our in vitro results demonstrating that AD+TS treatment 
reduces tumor incidence. We observed a decrease in active β-catenin following AD+TS 
treatment in monolayer, tumoroid, and in vivo tumors as well as signaling intermediaries 
downstream of β-catenin including phospho-AKT, and phospho-MAPK. We also 
identified decreased activation of an upstream activator of β-catenin, LRP6, further 
supporting the downregulation of canonical Wnt/ β-catenin signaling. A summary of 
these effects can be seen in figure 37. Additionally, ROS generation was increased by 
AD+TS treatment, which offers a possible mechanism for the observed induction of 
apoptosis and changes in Wnt signaling, but further investigation is needed in this area. 
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Taken together, the results presented in these studies have highlighted the importance 
of NPRA and Wnt/ β-catenin signaling in the acquisition of CSC traits in lung cancer. 
The knowledge acquired from this study could be useful in the future to develop cancer 
therapies targeting CSC, and ultimately improving patient outcomes.   
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